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ABSTRACT 
Acute respiratory infections (ARI) continue to be the leading cause of acute illnesses 
worldwide and remain the most important cause of infant and young children 
mortality. Many viruses such as rhinoviruses, influenza viruses, parainfluenza viruses, 
respiratory syncytial viruses, adenoviruses and coronaviruses are deemed to be the 
etiological agents responsible for ARI’s in children. The recently discovered 
coronaviruses HCoV-HKU1 and HCoV-NL63 contribute significantly to the 
hospitalization of children with ARI’s. 
HCoV-NL63 was first identified in 2004, as the pathogen responsible for the 
hospitalization of a 7 month old child presenting with coryza, conjunctivitis and fever. 
Since then a significant amount of knowledge has been gained in the clinical spectrum 
on this virus, however HCoV-NL63 is still not well characterized on the molecular 
and proteomic level. 
This dissertation focuses on bringing about this characterization by cloning the 
HCoV-NL63 Nucleocapsid gene to be expressed in a bacterial system and 
transfecting the Nucleocapsid, Membrane and Envelope genes into a Mammalian cell 
culture system in order for its respective proteins to be expressed. With the use of 
Bioinformatic analytic tools certain characteristics of HCoV-NL63 Nucleocapsid, 
Membrane and Envelope proteins are able to be identified, as well as certain motifs 
and/or regions that are important in the functioning of these proteins. By comparing 
the results obtained for HCoV-NL63 N,M and E to other well studied coronavirus 
homologous will enlighten us on the potential role(s) of these proteins in determining 
HCoV-NL63 pathogenicity and infectivity. 
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Although certain functions of these proteins can be deduced by the means of 
bioinformatics analysis, it is still imperative for it to be extensively characterized In 
Vitro. This will therefore form a fundamental step in the development of many other 
projects, which unfortunately fall outside the scope of this M.Sc thesis.          
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1. Introduction 
 
Acute respiratory illnesses (ARIs), also known as acute respiratory infections, are a 
major international health concern. As a group, ARIs affect all age groups and 
account for approximately 4 million worldwide deaths annually. These deaths place 
an economic burden on nations’ health care systems, especially those in third world 
countries. Viruses such as rhinoviruses, influenza viruses, parainfluenza viruses, 
respiratory syncytial viruses, adenoviruses and coronaviruses have been shown to be 
most frequently associated with respiratory infections (Bryce et al. 2005). 
It has previously been reported that human coronaviruses account for a significant 
number of hospitalisations for children under 18 years of age, accounting for 4.4% of 
all admissions for acute respiratory infections (Chiu, Chan et al. 2005).  
Human coronaviruses (HCoVs) are considered as among the leading causes of ARIs. 
HCoVs were first isolated in the 1960s, and since then have not only been found to be 
mainly associated with respiratory tract illnesses, but can also cause diseases of the 
enteric and central nervous systems (Wu, Chang et al. 2008).  
Until recently, only two human coronaviruses were known to science, i.e. HCoV-
229E and HCoV-OC43. With the outbreak of Severe Acute Respiratory Syndrome 
(SARS) in 2003, a third and previously unknown coronavirus was identified as the 
aetiological agent. The SARS coronavirus eventually spread from China to more than 
30 countries, and resulted in more than 800 fatalities worldwide; this equated to an 
about 10% mortality rate. Then in 2004, a fourth human coronavirus was isolated 
from a 7-month-old child with respiratory symptoms. This virus was identified as a 
close relative of SARS-CoV and was named human coronavirus-NL63 (Pyrc, Jebbink 
et al. 2004). Other groups independently reported the presence of essentially the same 
virus in children, calling it HCoV-NL (Fouchier, Hartwig et al. 2004) and HCoV-NH 
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(Esper, Weibel et al. 2005), respectively; in this dissertation it will be referred to as 
human coronavirus-NL63 (HCoV-NL63). 
1.1. The Discovery of Coronaviruses 
The first coronavirus (CoVs), responsible for infectious bronchitis in chickens, was 
identified in 1937 by Beudette and Hudson by isolating the virus in chick embryos 
(Beaudette and Hudson, 1937). Corona-virology has advanced significantly since then 
with the discovery of more coronaviruses, especially human coronaviruses. 
In 1965 Tyrell and Bynoe found that they could passage a virus known as B814 (Tyrrell, 
Bynoe et al. 1968; Kahn and McIntosh 2005). It was isolated in an adult with a common 
cold and then cultured in human embryonic tracheal organ cultures. The presence of 
an infectious agent was demonstrated by inoculating the medium from these cultures 
intranasal in human volunteers; in turn, colds were produced in a signiﬁcant number 
of subjects, but Tyrell and Bynoe were unable to grow the agent in tissue culture at 
the time. It was Hamre and Procknow who set it apart as they were able to grow a 
virus with atypical properties in tissue culture from samples obtained, specifically 
from medical students with colds (Hamre and Procknow 1966; Pyrc, Berkhout et al. 
2007). Both B814 and the virus that Hamre had discovered, called 229E, were ether 
sensitive and therefore most probably required a lipid-containing coat for infectivity, 
but these 2 viruses were not related to any known myxo- or paramyxoviruses (Hamre 
and Procknow 1966; Kahn and McIntosh 2005). 
McIntosh et al had discovered multiple strains of ether-sensitive infectious agents 
from the human respiratory tract, using a technique similar to that of Tyrell and 
Bynoe, and designated the viruses as ‘OC’ because it was grown in organ cultures 
(McIntosh, Dees et al. 1967; Kahn and McIntosh 2005). These findings together led to 
the discovery of the first human coronaviruses, namely 229E and OC43, which were 
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extensively studied until the outbreak of SARS. As microscopy was not, at the time of 
Tyrell and Benoe’s study, as advanced as it is today, many viruses resembled each 
other and were grouped together incorrectly. This appeared to be the case with 
coronaviruses as well. It was only in 1975 that coronaviruses were finally accepted as 
a new genus (Pyrc, Berkhout et al. 2007). 
 
1.2. SARS and coronavirus research  
In 2003, the emergence of Severe Acute Respiratory Syndrome brought the field of 
‘corona-virology’ back into the spotlight (McIntosh 2005). It seemed clear that this 
new disease, inimitable in its clinical spectrum, had resulted from the movement of an 
animal CoV across the species barrier; it was found the virus had spread in the human 
population through a process of adaptation by deletion and mutation (Kuiken, 
Fouchier et al. 2003; Peiris, Lai et al. 2003; McIntosh 2005). 
 Towards the end of June 2003, patients from 29 countries had been diagnosed with 
SARS, with the majority of these cases reported in Asia.  Because of the absence of 
an effective source of treatment, the disease was combated using only quarantine 
measures and travel restrictions. This, however, proved to be an effective strategy and 
the SARS epidemic was halted in June 2003. the death toll had climbed to 774 out of 
8098 reported infections, and the disease had caused massive economic harm (Stadler, 
Masignani et al. 2003). The efforts to control SARS were matched by a multi-centred, 
collaborative effort by scientists to identify and analyse the infectious agent that 
caused the disease (Hofmann, Pyrc et al. 2005). The collaborative research had 
culminated in the identification of a novel coronavirus (CoV) in SARS patients 
(Kuiken, Fouchier et al. 2003; Peiris, Lai et al. 2003); thereafter it was demonstrated 
that the virus had been the cause of the disease (Fouchier, Kuiken et al. 2003; Kuiken, 
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Fouchier et al. 2003). Shortly after the discovery of SARS, the virus sequence was 
made available to the public (Marra, Jones et al. 2003; Rota, Oberste et al. 2003), 
which led to the analysis and eradication of SARS at a molecular level (Hofmann, 
Pyrc et al. 2005). 
The characterisation of SARS-CoV revealed that highly pathogenic human CoVs 
(HCoVs) can evolve as result of its ability to mutate. Therefore the identification and 
characterisation of new HCoV species is a critical objective as it could prevent future 
epidemics. 
 The SARS-CoV is, allegedly, no longer circulating among humans. However, at least 
four other coronaviruses are continuously making its rounds in the human population, 
especially among young children. Two of the four coronaviruses were recently 
discovered: HCoV-NL63 and HCoV-HKU1(Krzysztof Pyrc 2004; van der Hoek, Pyrc 
et al. 2004; Woo, Lau et al. 2005). The other two, HCoV-OC43 and HCoV- 229E, 
were identified in the mid-1960s as previously described (Hamre and Procknow 1966; 
Tyrrell, Bynoe et al. 1968). The latter viruses were tested for pathogenicity in human 
volunteers, which demonstrated that HCoV-229E and HCoV-OC43 cause the 
common cold (Bradburne, Bynoe et al. 1967). For now, the new viruses – HcoV-
NL63 and HCoV-HKU1 – are lacking human and animal test model systems.  
Since the discovery of HCoV-NL63 in 2004, much has been learnt this virus. Several 
groups have studied the global spread, the association with human disease, and the 
replication characteristics of HCoV-NL63 (van der Hoek and Berkhout 2005; van der 
Hoek, Pyrc et al. 2006). These virus characteristics are still to be defined on a 
molecular level, though. 
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1.3. Human Coronavirus NL63 (HCoV-NL63) 
1.3.1. The Discovery of HCoV-NL63 
In January of 2003, a 7-month-old child was hospitalised in Amsterdam with signs 
and symptoms of coryza, conjunctivitis and fever (van der Hoek, Pyrc et al. 2006). 
The prognosis was as follows: A chest radiograph showed typical features of 
bronchiolitis; a nasopharyngeal aspirate collected five days after the onset of the 
disease had tested negative for all known respiratory viruses. The clinical sample 
collected was then inoculated onto tertiary monkey kidney cells (tMK; Cynomolgus 
monkey) and a cytopathic effect was observed. The infectious agent could then 
subsequently be passaged onto LLC-MK2 cells (a monkey kidney cell line). Lia van 
der Hoek and her colleagues then identified the virus in the supernatant of the LLC-
MK2 cell culture by means of the VIDISCA (Virus Discovery cDNA-AFLP) method 
(van der Hoek, Pyrc et al. 2004). This is a novel viral discovery technique that utilises 
the restriction of cDNA generated by RT-PCR of isolated viral RNA. As the 
restriction sites are known, the digested fragments can be amplified with specific 
primers (Fig 1.1) (van der Hoek, Pyrc et al. 2004). The PCR products obtained from 
this technique had revealed sequence similarity to the genome sequences of members 
of the coronaviridae family. The analysis of the virus genome had also shown that 
this virus was not a recombinant but rather a new member of the group I 
coronaviruses (van der Hoek, Pyrc et al. 2004; Pyrc, Berkhout et al. 2007). 
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Figure 1.1: The VIDISCA method used to discover HCoV-NL63. This is a viral discovery 
technique that utilizes the restriction of cDNA generated by RT-PCR of isolated viral RNA. As the 
restriction sites are known the digested fragments can be amplified with specific primers(van der Hoek, 
Pyrc et al. 2004). 
 
A second research group in the Netherlands described the same virus shortly after the 
first publication on HCoV-NL63 had been released. Fouchier and colleagues had 
described a virus (which they named HCoV-NL) in a Vero-E6 cell culture supernatant 
(Fouchier, Hartwig et al. 2004). But this virus had been isolated in 1988 from a nose 
swab sample from an 8-month-old boy suffering from pneumonia. It was also 
cultivated first on tMK cells and then subsequently passaged onto Vero cells. There 
was a very high similarity (98.8% at the molecular level) with the previously 
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described HCoV-NL63 strain, and it was concluded that these two virus isolates had 
represented the same species. This implies that HCoV-NL63 had been circulating in 
the human population for many years before its first discovery. Most of the 
differences between the two virus variants are clustered in the amino terminal region 
of the spike protein (van der Hoek, Pyrc et al. 2004; Pyrc, Berkhout et al. 2007). 
Almost one year later, a third group had described the same human coronavirus 
(Esper, Weibel et al. 2005). This virus was identified (in New Haven, CT, USA) by 
screening patient samples with the use of universal coronavirus primers. But these did 
not match at a nucleotide level with HCoV-229E, HCoV-OC43 or SARS-CoV (van 
der Hoek and Berkhout 2005). Therefore, Esper and colleagues had named their virus 
the New Haven Coronavirus (HCoV-NH), even though the partial sequences of their 
isolates are very similar to the isolates from The Netherlands (94–100% identical at 
the nucleotide level) and therefore represent the same species (van der Hoek and 
Berkhout 2005). 
Literature of the early coronaviruses indicates that HCoV-NL63, or the novel group II 
virus HCoV-HKU1, may have been previously observed (van der Hoek and Berkhout 
2005; Pyrc, Berkhout et al. 2007). In some of the initial work done on human 
coronaviruses sometime during the mid-1960s, viruses could be propagated in human 
embryonic tracheal organ cultures that were not, or only distantly, related to HCoV-
229E or HCoV-OC43 (McIntosh, Dees et al. 1967; Tyrrell, Bynoe et al. 1968). 
Unfortunately these strains B814 (Tyrrell, Bynoe et al. 1968), HCoV-OC16, HCoV-
OC37, and HCoV-OC48 (McIntosh, Dees et al. 1967) had been lost for follow-up 
research, so it remains unsure if those viruses had represented HCoV-HKU1 or 
HCoV-NL63, or perhaps some still-to-be-discovered human coronaviruses (Van der 
Hoek and Berkhout, 2005).  
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At the start of the 1980s, studies were conducted on several isolates of human 
coronaviruses that had been obtained by either cell culture or organ culture 
(Macnaughton, Flowers et al. 1983; van der Hoek and Berkhout 2005).  
A number of those isolates were serologically related to HCoV-OC43, and were 
therefore termed group II isolates, whereas those serologically related to HCoV-229E 
were assigned as group I isolates (Van der Hoek and Berkhout 2005; van der Hoek, 
Pyrc et al. 2006).  
A few of the group I viruses assigned as strains – LP, KI, PR and TO – could be 
cultured in MRC continuous cells (human), but two of the strains known as AD and 
PA could only be cultured in human foetal tracheal and nasal organ cultures. 
According to Van der Hoek et al, the difference in culture properties reflects the 
difference in cell tropism of HCoV-229E and HCoV-NL63, and so raises the 
possibility that some of the earlier group I strains were actually HCoV-NL63 isolates 
(van der Hoek and Berkhout 2005; van der Hoek, Pyrc et al. 2006). Because Van der 
Hoek and her colleagues had lost the isolates AD and PA, this hypothesis could not be 
tested. The NL strain remains the earliest isolate of HCoV-NL63, which had been 
obtained from a patient in 1988. This was later, in 2004, identified as HCoV-NL63 
(Fouchier, Hartwig et al. 2004; van der Hoek, Pyrc et al. 2004). 
1.3.2 HCoV-NL63 Infection 
Literature indicates that infection with HCoV-NL63 happens often (Fouchier, Hartwig 
et al. 2004; van der Hoek, Pyrc et al. 2004; Fielding 2011; Leung, Chan et al. 2012), 
with many reports revealing upper and lower respiratory tract illnesses in infected 
patients. 
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HCoV-NL63 has also shown a worldwide prevalence, as it has been reported to cause 
infection in various countries (Fouchier, Hartwig et al. 2004; Esper, Weibel et al. 
2005; Vabret, Mourez et al. 2005; van der Hoek, Pyrc et al. 2006; Fielding 2011).  
In Australia it had been reported that infection with HCoV-NL63 was detected in 16 
out of 766 patients who had presented with acute respiratory disease (van der Hoek, 
Pyrc et al. 2004; Arden, Nissen et al. 2005).  
A study done in Japan, by Ebihara and colleagues on 118 children under the age of 
two who had been hospitalised for bronchiolitis, had shown that three patients had 
tested positive for HCoV-NL63 (van der Hoek 2007). A second Japanese study 
indicated the presence of HCoV-NL63 in 5 out of 419 respiratory tract specimens 
collected from children with respiratory infections (Suzuki, Okamoto et al. 2005). 
Reports in Belgium indicated HCoV-NL63 infections in 7 out of 279 children 
hospitalised with upper and lower respiratory tract illnesses (Moes, Vijgen et al. 
2005). A study done in France had shown 28 out of 300 patients presenting with 
upper and lower respiratory tract illnesses under the age of 20 tested positive for 
HCoV-NL63 (Vabret, Mourez et al. 2005). 
In Switzerland, research done on neonates had identified HCoV-NL63 in 6 out of 82 
children during their first episode of lower respiratory tract illness (Kaiser, Regamey 
et al. 2005; van der Hoek, Ihorst et al. 2010). Two separate studies in Canada reported 
45 patients had tested positive for HCoV-NL63 out of a total of 1765 specimens 
(Bastien, Anderson et al. 2005; Bastien, Robinson et al. 2005; van der Hoek, Sure et 
al. 2005). 
In Hong Kong a report compiled by Chiu and his colleagues in 2005 indicated that 
HCoV-NL63 had been detected in 5 out of 587 children. These children had 
participated in a prospective study on children under the age of 18 with acute 
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respiratory tract infection. The study group was a good representation of the 
population in Hong Kong, and proposed that HCoV-NL63 causes infection in more 
than 200 hospitalised cases per 100 000 children all under the age of 6 (Chiu, Chan et 
al. 2005; van der Hoek, Sure et al. 2005). 
German researchers had reported 49 samples had tested positive for HCoV-NL63 
from 949 samples taken from children with lower respiratory tract illness; these 
children had participated in the PRI.DE (Paediatric Respiratory Infection in Germany) 
study (van der Hoek, Sure et al. 2005). 
Based on these reports, it can be deduced that HCoV-NL63 can cause infection in the 
age range of 1 month to 100 years, with the highest proportion of positive specimens 
between the ages of 0-5 years. 
This virus has also been implicated as the causative organism in illnesses other than 
upper and lower respiratory tract infections. Reports show that HCoV-NL63 is 
frequently observed to cause infection in patients with underlying illnesses, such as 
those who are immunocompromised because of therapies, the HIV-infected or those 
with other medical conditions such as chronic obstructive pulmonary disease 
(Fouchier, Hartwig et al. 2004; Arden, Nissen et al. 2005; Bastien, Anderson et al. 
2005; Moes, Vijgen et al. 2005; van der Hoek, Sure et al. 2005).  
1.3.3. HCoV-NL63: Possible association with specific diseases: 
1.3.3.1. Croup 
Croup, also known as laryngotracheitis, is indicated as inflammation of the trachea 
and is associated with a characteristic loud barking cough that may get worse at night. 
Croup is a common manifestation of lower respiratory tract illness among children. 
Respiratory viruses such as PIV1 have frequently been implicated as the cause 
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(Denny, Murphy et al. 1983; van der Hoek, Sure et al. 2005). There is much debate on 
whether HCoV-NL63 is the causative organism of croup. It hasn’t yet, however, been 
ascertained if it is the causative organism even though research strongly supports this 
theory. Some researchers believe that there is a clear link between the two. A 
prospective population-based study done in Germany known as PRI.DE, which 
looked at lower respiratory tract illness among children younger than 3 years of age, 
had established a clear link between HCoV-NL63 and respiratory diseases (van der 
Hoek, Sure et al. 2005). The study had shown that HCoV-NL63 infection is strongly 
associated with croup. About half of the patients that tested positive for HCoV-NL63 
were diagnosed with croup, and an even higher portion of the samples collected from 
patients with croup contained HCoV-NL63 RNA (17.4%), when compared to patients 
who did not have croup (4.2%, P< 0.0001) (van der Hoek, Sure et al. 2005). 
Croup has been reported to occur most frequently in boys and predominantly in the 
second year of life (Denny, Murphy et al. 1983). A trend is seen to be followed by 
HCoV-NL63-infected patients: the ratio of boys to girls infected is 10:4, the median 
age in the outpatient group with HCoV-NL63 is 1.55 years, and it has been shown to 
mostly occur during the winter season (van der Hoek, Sure et al. 2005). 
In a study with 69 samples of patients analysed with croup, croup had been frequently 
linked to PIV1 (14.5%), but PIV3 (15.9%), RSV-A (13.0%), PIV2 (7.2%), and RSV-
B (1.4%) were also detected in a substantial fraction of the samples(van der Hoek, 
Sure et al. 2005). HCoV-NL63 could be detected in 17.4% of these croup patients and 
was therefore the most frequently identified respiratory virus for croup (van der Hoek, 
Sure et al. 2005). 
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1.3.3.2. Kawasaki Disease (KD) 
In the developed world, KD is the most common cause of acquired heart disease in 
children (Baker, Shimizu et al. 2006; Dominguez, Anderson et al. 2006; van der 
Hoek, Sure et al. 2006; Pyrc, Berkhout et al. 2007). It presents with prolonged fever 
and a polymorphic exanthema, oropharyngeal erythema, and bilateral conjunctivitis. 
A number of epidemiological and clinical observations previously suggested that an 
infectious agent might be the cause of KD (Burgner and Harnden 2005). But even 
though many infectious agents have been proposed as the cause of KD, none have 
been consistently associated with the disease (Esper, Shapiro et al. 2005). 
Esper et al., 2005, suggested that there is evidence that Kawasaki disease may be 
triggered by a response to an infectious agent. From hospital discharge records, they 
identified 53 children who were diagnosed with Kawasaki disease. From these 
children they had received 11 respiratory specimens. 8 of the 11 patients all under the 
age of 4 years tested positive for HCoV-NL63 by RT-PCR. The researchers proposed 
that their data demonstrate that, in their population during the study period, there was 
a significant association between HCoV-NL63 infection and KD. 
In contrast to Esper et al’s results, a study conducted by Shimizu et al suggest that 
HCoV-NL63 is not associated with Kawasaki disease. Their study tested the possible 
association between HCoV-NL63 in the respiratory tract and acute KD by RT-PCR 
and viral culture of respiratory samples from a larger, geographically and ethnically 
diverse population. They tested 57 samples from 48 patients; only 1 tested positive for 
HCoV-NL63, which shows no significant association between HCoV-NL63 and KD 
(Shimizu, Shike et al. 2005). 
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There is, however, a fascinating link between HCoV-NL63 and Kawasaki disease. 
According to van der Hoek et al., 2006, multiple groups had screened for the presence 
of HCoV-NL63 in respiratory material of patients with Kawasaki disease (KD); they 
would not, however, confirm the findings of Esper et al (Belay, Erdman et al. 2005; 
Esper, Shapiro et al. 2005; Shimizu, Shike et al. 2005; Ebihara, Endo et al. 2005b; 
Wu, Chang et al. 2008). 
The use of synthetic antibodies by Rowley et al had identified an antigen in 
respiratory epithelial cells and macrophages from children who were diagnosed with 
Kawasaki disease (Rowley, Shulman et al. 2005). The origin of this antigen remains 
unknown.  
So whether or not HCoV-NL63 is associated with Kawasaki disease remains an open 
question, and future studies should continue to investigate the possibility of a 
respiratory portal of entry as the etiological agent of Kawasaki Disease. 
1.3.4. Co-infection of HCoV-NL63 with other viruses  
Co-infection of HCoV-NL63 with other respiratory viruses is reported to be a 
common occurrence, especially with other human coronaviruses, Influenza A virus, 
respiratory syncytial virus (RSV), parainfluenza virus and human metapneumovirus 
(hMPV) (Chiu, Chan et al. 2005; Kaiser, Regamey et al. 2005; Dare, Fry et al. 2007; 
Lambert, Allen et al. 2007; Canducci, Debiaggi et al. 2008; Minosse, Selleri et al. 
2008; Wu, Chang et al. 2008; Abdul-Rasool and Fielding 2010; van der Hoek, Ihorst 
et al. 2010). It has been reported that co-infected patients are more likely to be 
hospitalised, thus indicating how severe a superinfection of this kind could be.  
In a German study, co-infection of HCoV-NL63 with RSV-A was shown to be the 
most common co-infection identified in children under the age of 3 years. This is said 
to be probably due to the high incidence of RSV-A in winter and the possible overlap 
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in the seasonality of the viruses (van der Hoek 2007; Abdul-Rasool and Fielding 
2010). In Italy it has been reported that HCoV-NL63 circulates as a mixture of variant 
strains and is also often associated with other viral infections (Minosse, Selleri et al. 
2008; Abdul-Rasool and Fielding 2010). Co-infection of patients with HCoV-NL63 
and Bacovirus has been reported among hospitalised children in South Africa. 
Respiratory tract samples from 341 patients were screened for common respiratory 
viruses, and the co-presence of HCoV-NL63 and bocavirus in at least one sample had 
been reported (Smuts 2008; Abdul-Rasool and Fielding 2010). 
Research has shown that, in co-infected patients the viral load of HCoV-NL63 is 
lower than in patients infected with only HCoV-NL63. There seems to be a variety of 
possibilities for this phenomenon (van der Hoek 2007; Abdul-Rasool and Fielding 
2010). Infection with HCoV-NL63 could be the initial infection that weakens the 
immune system to the degree that a second infection may gain a foothold. So by the 
time the secondary infection shows symptoms, the initial infection with HCoV-NL63 
might have already been brought under control by the host immune system. The two 
viruses could also be in competition for the same target cells or receptors in the 
respiratory organs. The increase in the activation of the host innate immune response 
could be triggered by the second respiratory virus, thereby causing inhibition of 
HCoV-NL63 or lastly. The prolonged persistence of HCoV-NL63 could be at low 
levels. 
The high rate of co-infection of HCoV-NL63 and other respiratory viruses may 
increase the chances of genetic recombination with these human or zoonotically 
transmitted viruses. It has been reported by Pyrc et al (2006) that HCoV-NL63 
resulted from a recombination event between PEDV and an ancestral HCoV-NL63 
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strain (Pyrc, Bosch et al. 2006). Hypothetically, these types of recombination may 
enable the formation of highly pathogenic virus variants (Pyrc, Dijkman et al. 2006; 
Abdul-Rasool and Fielding 2010). 
1.3.5. HCoV-NL63 Pathogenesis 
HCoV-NL63 infection is initiated by the recognition of a specific receptor on the host 
cell surface by the Spike protein. This is followed by the internalisation of the virus, 
which may occur immediately by the direct fusion of the virus with the plasma 
membrane of the host cell or after endocytosis (Pyrc, Bosch et al. 2006; Pyrc, 
Berkhout et al. 2007). The fusion of the viral membrane with the cellular membrane 
activates the release of the viral RNA genome into the host cell cytoplasm. The viral 
RNA is then copied by the viral replicase in the membrane-associated replication 
centres (Pyrc, Bosch et al. 2006; Abdul-Rasool and Fielding 2010). During the 
replication process, copies of full length genomic RNA as well as a nested set of sub-
genomic mRNA are generated. These subgenomic mRNAs serve as functional 
templates for the translation of the structural proteins that are encoded in the 3’ one 
third of the genome. The full-length viral RNA then becomes encapsulated and is 
released from the host cell as an infectious virus particle. Further investigation of 
HCoV-NL63 pathogenicity seems warranted, as the virus shares the same cellular 
receptor as SARS-CoV (Li, Sui et al. 2007; Pyrc, Berkhout et al. 2007).  
1.3.6. HCoV-NL63 Genome Organization 
HCoV-NL63 has a very large, single stranded RNA genome that is made up of 27533 
nucleotides; it is also capped and polyadenylated (Pyrc, Berkhout et al. 2007; Abdul-
Rasool and Fielding 2010). It has a GC content of 34% and a coronavirus GC content 
that typically ranges between 32 to 42%; therefore HCoV-NL63 GC content is one of 
the lowest (van der Hoek, Pyrc et al. 2004; Pyrc, Berkhout et al. 2007). There are 
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untranslated regions of 286 and 287 nucleotides that are found at the 5’ and 3’ termini 
respectively (Pyrc, Berkhout et al. 2007). The genome of HCoV-NL63 follows a 
specific order, namely 5’-ORF1a-ORF1b-S-ORF3-E-M-N-PolyT-3’ (Fig 2). 
 
 
 
 
 
 
 
 
 
 
Fig 1.2: Genomic structure of HcoV-NL63: The 27553 nucleotide genome is subdivided into 
replicase and structural genes. The arrow at nucleotide 12439 indicates the position of the -1 
ribosomal frameshift that is required to fully express ORF’s 1a and 1b. The figure is also 
indicative of the 5 subgenomic mRNA’s that are expressed by the structural and accessory 
genes, all with the same 5’ UTR (Pyrc, 2004). 
 
There are six mRNAs that produce seven distinct ORFs. This includes the full-length 
genomic RNA and a nested set of five subgenomic mRNAs (Pyrc, Jebbink et al. 
2004). Coronaviruses are said to generate their mRNAs in the membrane- associated 
replication centres (Woo, Lau et al. 2005). The genes that are predicted to encode the 
Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N) proteins are found at 
the 3’ part of the HCoV-NL63 genome (Pyrc, Jebbink et al. 2004; Pyrc, Berkhout et 
al. 2007). Some group II coronaviruses contain an HE gene which is not present in 
HCoV-NL63; there is only a single, monocistronic accessory protein ORF (ORF 3) 
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that is located between the E and S genes (Pyrc, Jebbink et al. 2004; Pyrc, Berkhout et 
al. 2007). 
There are five subgenomic mRNAs that encode for the viral structural and accessory 
proteins S, ORF 3, E, M and N. A common transcription regulatory sequence (TRS), 
which contains a core sequence AACUAAA, is located upstream of all the ORFs, 
with the exception of ORF E. It has been known that this TRS is crucial for the 
formation of sg mRNA (Pyrc, Berkhout et al. 2007; Abdul-Rasool and Fielding 
2010). 
During the minus strand synthesis, HCoV-NL63 uses a discontinuous replication 
strategy to generate sg mRNAs (Pyrc, Jebbink et al. 2004; Pyrc, Berkhout et al. 2007). 
This is then copied into plus strand mRNAs. All plus strand mRNAs share a common 
∼70 nucleotide leader sequence at their 5’ end that is identical to the sequence at the5’ 
end of the genomic RNA (Pyrc, Berkhout et al. 2007; Abdul-Rasool and Fielding 
2010).  
 
1.4. Coronaviruses 
Coronaviruses (CoVs) belong to the family Coronaviridae in the order nidovirales. 
These coronaviruses are divided into subgroups 1, 2 and 3, based mostly on genetic 
similarities (Abdul-Rasool and Fielding 2010). Coronaviruses are enveloped viruses 
with positive-sense, single-stranded, RNA genomes of 27 to 32 kb that are 5’ capped 
and 3’ polyadenylated (Pyrc, Jebbink et al. 2004; de Haan, Li et al. 2005). CoVs have 
a common genome organisation, in which the replicase gene encompasses the 5’ two-
thirds of the genome and is comprised of two overlapping open reading frames 
(ORFs), ORF1a and ORF1b. During coronavirus replication, a 3’-coterminal nested 
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set of subgenomic mRNAs, which encode  structural viral proteins such as  - spike (S) 
- envelope (E) - membrane (M) and nucleocapsid (N), are synthesised. Some group II 
CoVs carry an additional structural protein that encodes a hemagglutinin esterase. The 
gene is located between the ORF1b and S gene (Wurm, Chen et al. 2001). Expression 
of non-structural replicase proteins has been shown to be mediated by translation of 
the genomic RNA that in turn gives rise to the biosynthesis of two large polyproteins, 
namely pp1a, which is encoded by ORF1a and pp1ab; these are facilitated by a 
ribosomal frameshift at the ORF1a/1b junction. In contrast, the structural proteins are 
translated from subgenomic mRNAs. These subgenomic mRNAs are the result of 
discontinuous transcription, a specific feature of CoV gene expression (Dijkman, 
Jebbink et al. 2008). The structural gene region harbours several ORFs that are 
interspersed along the structural protein coding genes. The number and location of 
these accessory ORFs vary between the CoV species (Stanley G. Sawicki 2007). 
1.4.1. Coronavirus Nucleocapsid Protein 
During the coronavirus life cycle, the N protein is synthesised in large amounts and is 
thought to play an important role by specifically packaging the viral genome into a 
filamentous nucleocapsid of ~10 to 15 nm in diameter and several 100 nm in length, a 
macromolecular structure that is visible by electron microscopy (Lai 1997; Almazan, 
Galan et al. 2004). In addition to its structural role, the N protein also participates in 
viral RNA transcription, replication and in modulating the metabolism of host cells 
(Baric, Nelson et al. 1988; Hall 2002). 
The highly basic N protein has a molecular mass ranging between 45 and 60 kDa in 
the various groups of coronaviruses and, along with its coding RNA, is synthesised in 
large amounts during infection (Kuo and Masters 2003; Narayanan, Kim et al. 2003). 
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The N protein is able to bind ssRNA nonspecifically, but displays an increased 
affinity for viral genomic RNA (Narayanan, Kim et al. 2003; Hsieh, Chang et al. 
2005). Three groups of coronaviruses have been identified to date, although sequence 
conservation of the N proteins within the genus is low. For instance, the N proteins of 
coronaviruses IBV (group III) and porcine transmissible gastroenteritis virus (TGEV; 
group I) have only 29% identity with that of bovine coronavirus (BCoV; group II) 
and, within the group II coronaviruses, the N proteins of MHV and BCoV have only 
70% identity (Lapps, Hogue et al. 1987). Several functions have been postulated for 
the coronavirus N protein throughout the virus life cycle, such as its various protein-
protein interactions as discussed below. 
 
1.4.2. N- Terminal-Domain and C-Terminal-Domains involvement in RNA 
Binding 
The N protein is an essential structural component of the virion; this protein plays 
important roles in packaging the RNA genome to form a ribonucleoprotein (RNP) 
complex resulting from assembly of the viral RNA and multiple copies of the 
nucleocapsid protein. A meticulous dissection and characterisation of the intrinsic 
RNA-binding properties of these proteins are vital for understanding several 
important processes in the life cycle of RNA viruses, including assembly of the 
nucleocapsid, the specific encapsidation of viral RNA and the morphogenesis of 
virions (Arciola, Campoccia et al. 2006). 
According to biochemical studies, the RNA binding site is found in the N-terminal 
domain (Risco, Anton et al. 1996; Lai 1997; Risco, Anton et al. 1998). The C-
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terminal domain is also involved in RNA binding and this was shown by Fan et al 
(Baric, Nelson et al. 1988). The N-terminal-domain of the IBV Gray strain has shown 
to exhibit a U-shaped structure, with two arms rich in basic residues at a 1.3-Å 
resolution, thus providing a specific component for interaction with RNA (Kuo and 
Masters 2003). The C-terminal-domain has shown to form a tightly intertwined dimer 
containing a central, intermolecular four-stranded β-sheet platform flanked by α-
helices, thus indicating that a dimeric assembly of the N protein forms the basic 
building block for coronavirus nucleocapsid formation (Kuo and Masters 2003). 
According to Narayanan et al., the array of quaternary arrangements of the NTD and 
CTD revealed by the analysis of the different crystal forms could delineate possible 
interfaces that could be used for the formation of a flexible filamentous 
ribonucleocapsid (Narayanan, Kim et al. 2003). 
1.4.3. Interaction between the N and M proteins 
The importance of M–N interaction in viral interaction appears to be an essential 
process for coronavirus assembly as coronaviruses differ from other enveloped 
viruses such as paramyxoviruses and rhabdoviruses in that they lack the structural 
matrix protein that usually links the envelope to the nucleocapsid. Thereby, it can be 
envisaged that replacing the matrix protein in the role of core stabilisation through 
nucleocapsid binding appears to be one of the functions of the coronavirus M protein 
(He, Leeson et al. 2004). 
Multiple copies of the nucleocapsid (N) phosphoprotein interact intimately with 
genomic and subgenomic RNA molecules during the virus life cycle (Fan, Ooi et al. 
2005; Jayaram, Fan et al. 2006; Luo, Chen et al. 2006), and together with the M 
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protein, which is the most abundant envelope protein, participate in genome 
condensation and packaging. The interaction region between these two proteins has 
been mapped to their C termini (Masters, Kuo et al. 2006) by means of a reverse 
genetic-complementation assays (Jayaram, Fan et al. 2006). The C terminus of the M 
protein is known to be considerably basic, and a recent mutational study on the M 
protein has demonstrated that interactions between the N protein and M protein are 
predominantly electrostatic in nature (Baric, Nelson et al. 1988). Jayaram et al has 
demonstrated that the exposed acidic β-sheet floor, on the opposite side of the 
proposed RNA-binding region in the C-Terminal-Domain dimer, may promote such 
an interaction. This shows that the C-terminal-domain may serve a double purpose of 
mediating the self-association of the N protein during nucleocapsid formation, but 
also provides a corresponding surface for interaction with the endo-domain of the M 
protein in the virus envelope.  
1.4.4. Phosphorylation of the Nucleocapsid protein 
Coronavirus N proteins have a high (7 to 11%) serine content; serines are potential 
targets for phosphorylation (Laude, Godet et al. 1995). Between the two functional 
domains (CTD and NTD) is a segment containing several arginine/serine (RS) 
dipeptides that is structurally flexible. It is proposed that this RS-rich motif is an 
attribute of cellular precursor mRNA (pre-mRNA) splicing factors known as SR 
proteins (Fu 1995). The RS domain is phosphorylated with dynamism by several SR 
protein specific kinases, such as those belonging to the SR protein kinase (SRPK) and 
Clk families (Stojdl and Bell 1999). It has been shown that the phosphorylation of the 
RS domain modulates the activity, protein–protein interactions and subcellular 
localisation of SR proteins (Graveley 2000). Coronavirus N proteins are 
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phosphorylated in both host cells and in virions (Wootton, Rowland et al. 2002; Chen, 
Gill et al. 2005; White, Yi et al. 2007) and it has been reported that phosphorylation 
affects the RNA binding specificity and the nucleo-cytoplasmic shuttling of the N 
proteins (Chen, Gill et al. 2005; Surjit, Kumar et al. 2005). Phosphorylation can occur 
within the RS motif of coronavirus N proteins (Calvo, Escors et al. 2005; Surjit, 
Kumar et al. 2005) and thus may play a role in C-terminal domain dimerisation (Luo, 
Ye et al. 2005). Whether or not phosphorylation of the RS motif can modulate the 
functions of N proteins remains to be examined in detail.  
1.4.5. Localisation of the Nucleocapsid protein 
Coronavirus N proteins are found to be localised to both the cytoplasm and the 
nucleolus in virus-infected cells (Hiscox, Wurm et al. 2001; Wurm, Chen et al. 2001) 
and can transfer between the nucleus and the cytoplasm (Timani, Liao et al. 2005). 
Nucleolar localisation of N protein requires regions in the protein that are rich in 
arginine residues and is likely cell cycle-dependent (Hiscox, Wurm et al. 2001; 
Wurm, Chen et al. 2001). The avian infectious bronchitis virus N protein is able to 
interact and co-localise with the nucleolar proteins such as nucleolin and fibrillarin 
(Chen, Gill et al. 2005; Dove, You et al. 2006; Reed, Dove et al. 2006).  
However, the ability of nucleolar localisation differs between N proteins of various 
coronaviruses. In the case of SARS-CoVN protein, it is poorly localised to the 
nucleolus (You, Dove et al. 2005). In a study done by Tsui-Yi Peng et al, it was found 
that the SARS-CoV N protein appeared in cytoplasmic stress granules (SGs) (Peng, 
Koetzner et al. 1995; He, Zheng et al. 2003). When eukaryotic cells encounter 
environmental stress, mRNA metabolism is reprogrammed, which enables it to adapt 
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to stress-induced damage. Translationally stalled mRNAs, together with a number of 
translation initiation factors and RNA-binding proteins, are deposited into SGs 
(Kedersha and Anderson 2002). 
Given that amino acid sequence conservation within the N protein of the three 
different coronavirus groups is low, the fact that N proteins from group I and group II 
coronaviruses also localise to the nucleolus suggests that nucleolar localisation may 
be of functional significance. 
In another study done on nucleolar localisation by Torsten Wurm et al in 2001, it was 
investigated if nucleolar localisation is a conserved feature among coronavirus N 
proteins and determined the consequences of N protein expression on host cell 
proliferation (Wurm, Chen et al. 2001). Their results show that association with the 
nucleolus is a common feature of the N proteins from the order Nidovirales. In 
addition, expression of N protein may lead to an inhibition of host cell proliferation 
and associated polyploidy in some cells, consistent with an inhibition of cytokinesis. 
1.4.6. Nucleocapsid protein involvement in viral Transcription and Replication 
The coronavirus N protein has shown to be involved in virus RNA synthesis by three 
lines of evidence. Firstly, the N protein is able to bind specific RNA sequences, this 
including the leader sequence, the TRS sequence, and sequences located at the 3’ end 
of the virus genome (Shi and Lai 2005). Secondly, a small fraction of the N protein 
distributed in the host cell cytoplasm co-localises with the RTC during the early 
stages of infection (van der Meer, Snijder et al. 1999; Bost, Carnahan et al. 2000). 
And thirdly, the presence of N protein either in cis or in trans is required for efficient 
CoV RNA synthesis (Almazan, Galan et al. 2004). A quantitative analysis of TGEV 
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replicon activity showed an increase of more than 100-fold when N protein was 
present in cis, and an increase of more than 1000-fold when N protein was present in 
trans (Almazan, Galan et al. 2004). The importance of the N protein was also 
emphasised when it was shown that the rescue of recombinant coronaviruses from 
cells transfected with infectious RNA was to a great extent enhanced by, if not 
dependent upon, the expression of N protein in the same cell (Yount, Curtis et al. 
2000; Casais, Thiel et al. 2001; Yount, Denison et al. 2002; Yount, Curtis et al. 2003). 
These annotations were followed up by experiments that showed that, in the absence 
of the N protein, HCoV-229E replicons expressing GFP from a subgenomic mRNA 
produced low levels of GFP and little or no amplification of the replicon. However, 
the expression of N protein in the same cells, in cis or in trans, significantly increased 
the number of transduced cells, the levels of GFP expression and thereby, the 
amplification of the replicon (Schelle, Karl et al. 2005). 
1.4.7. Coronavirus Membrane (M) protein 
The membrane (M) glycoprotein is known to be the most abundant structural protein 
(Cornelissen, van Woensel et al. 1998). It spans the membrane bilayer about three 
times, leaving a shortNH2-terminal domain outside the virus; this may also be 
exposed luminally in intracellular membranes, and a long COOH terminus known as 
the cytoplasmic domain inside the virion (Rottier, Brandenburg et al. 1984; Baudoux, 
Besnardeau et al. 1998). 
A study done on the M protein of SARS-CoV had showed that it consists of 221 
amino acids in length, and the gene sequence shares low homology with M proteins of 
other members of the coronavirus family. According to previous studies on 
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coronaviruses, the 25kDa M protein is an important and the most abundant structural 
protein, it is able to induce an antibody-dependent complement-mediated 
neutralisation reaction (Fang, Ye et al. 2005). The M protein also plays a predominate 
role in the envelope and naked virus particles assembly (Kuo and Masters 2003). 
Research has shown that the M protein contains highly conserved glycosylated 
sequences, and this may be due to the interaction between virus and host cells (de 
Haan, Kuo et al. 1998; de Haan, de Wit et al. 2002). In addition to this the M protein 
is characterised as having three domains; a short N-terminal ectodomain, a triple-
spanning transmembrane domain, and a C-terminal endodomain (Armstrong, 
Niemann et al. 1984; Fang, Ye et al. 2005). 
According to Narayanan and colleagues, mouse hepatitis virus assembly takes place at 
a few sites ie. The budding compartment and the smooth membranes of the 
intermediate compartment, which is found between the endoplasmic reticulum (ER) 
and the Golgi apparatus (Tooze, Tooze et al. 1984; Klumperman, Locker et al. 1994). 
The M protein itself is not able to determine the budding site; when M protein is 
expressed without the presence of other viral proteins, it migrates further than the 
budding compartment and localises in the late-Golgi complex (Klumperman, Locker 
et al. 1994). This is an indication of an unidentified viral factor(s) that restricts the 
migration of M protein to the budding compartment. A candidate that may cause 
restriction of the migration of M protein is the viral nucleocapsid. Narayanan and 
colleagues hypothesise that the binding of the nucleocapsid to M protein causes 
restriction of migration of the M protein to the budding compartment, and that this M 
protein-nucleocapsid interaction may facilitate the envelopment of the nucleocapsid at 
the budding compartment (Narayanan, Maeda et al. 2000). 
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1.4.8. Coronavirus Envelope Protein 
The E protein is small in size and expressed in low quantities in vivo (de Haan, 
Vennema et al.1998).While only 76 amino acids (aa) or so in length, research 
revealed that E protein (approximately 9 kDa) played a significant multifunctional 
role in the coronavirus virion life cycle (Bos, Luytjes et al. 1996; Vennema, Godeke 
et al. 1996; Shen, Wen et al. 2003). 
As a membrane protein, the E protein has a major biological function in the 
participation of the formation of the viral envelope. It also plays an important role in 
viral replication in some coronavirus viruses, such as in transmissible gastroenteritis 
coronavirus (TGEV) and in marine hepatitis virus (MHV) (Godet, L'Haridon et al. 
1992; Kuo and Masters 2003; Shen, Wen et al. 2003). In addition, it has been proven 
that E protein is related to the apoptosis of the E-protein-expressing cells in MHV 
(An, Chen et al. 1999; Shen, Wen et al. 2003). 
When CoV M and E proteins are co-expressed in cell culture it produces virus-like 
particles (VLPs) (Vennema, Godeke et al. 1996; Baudoux, Carrat et al. 1998; Corse 
and Machamer 2000; Huang, Yang et al. 2004; Bosch, de Haan et al. 2005; DeDiego, 
Alvarez et al. 2007). 
Several studies on VLPs agree that the formation of coronaviruses is mediated by just 
the M and the E proteins, and that neither S or N proteins play a vital role in virion 
morphogenesis (Bos, Luytjes et al. 1996; Baudoux, Carrat et al. 1998; Corse and 
Machamer 2000; de Haan, Vennema et al. 2000; Mortola and Roy 2004; Hurst, Kuo 
et al. 2005; Yang, Xiong et al. 2005; DeDiego, Alvarez et al. 2007). The exact role of 
the E protein in this process has not yet been determined (Hurst, Kuo et al. 2005), but 
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some evidence suggests an interaction between E and M (Baudoux, Carrat et al. 1998; 
Corse and Machamer 2000; Hurst, Kuo et al. 2005), while other publications suggest 
that E acts independently of M during the budding process (Maeda, Maeda et al. 
1999; Corse and Machamer 2000). 
There are conflicting reports on SARS-CoV about which proteins are required for the 
formation of VLPs (DeDiego, Alvarez et al. 2007). Some claim that E and M are 
required for the efficient assembly of these particles in insect cells (Ho, Lin et al. 
2004; Mortola and Roy 2004), whereas others suggest that M and N proteins, instead 
of the  E protein, play a key role in the formation of SARS-CoV-like particles in 
mammalian cells (Huang, Yang et al. 2004). 
A study done on a recombinant MHV with a deletion of the E gene had confirmed 
that the E gene plays a critical role in viral assembly (Fischer, Stegen et al. 1998). The 
MHV remained viable but had low infectivity and replicated poorly, proving that 
while it is nonessential for MHV, the E gene is required for the production of an 
infectious virus (Kuo and Masters 2003). However, in the case of porcine 
transmissible gastroenteritis virus (TGEV), disruption of the E gene is lethal to the 
virus, implying that it is a vital protein (Curtis, Yount et al. 2002; Ortego, Escors et al. 
2002; Hurst, Kuo et al. 2005). Apart from the described roles in virus assembly, the E 
protein has additional functions during infection (Weiss and Navas-Martin 2005). 
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Aims of this thesis: 
1. Bioinformatic analysis of HCoV-NL63 M, N and E.  
2. Cloning of HCoV-NL63 N gene for expression in a bacterial system. 
3. Optimisation of expression of HCoV-NL63 M, N and E in COS-7 cells. 
4. Comparison of HCoV-NL63 N expressed in a bacterial and mammalian 
system. 
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2. MATERIALS AND METHODS 
2.1 Bioinformatic analysis of HCoV-NL63 N, M and E proteins 
2.1.1 Multiple Sequence Alignment 
The protein sequences were selected from the following accession numbers in NCBI: 
HCoV-NL63 (DQ846901.1), SARS-CoV (AY360146.1), HCoV-OC43 
(AY585229.1), HCoV-229E (AAG48597), HKU1 (AAT98585). The selected amino 
acid sequences (Table 2.1) were aligned with CLUSTAL X version 2.0 (Larkin, 
Blackshields et al. 2007) and viewed with GeneDoc version 2.6.002 software  
(Nicholas and Nicholas 1997). 
 
Table 2.1: Human coronavirus structural proteins used for bioinformatics analysis 
HCoV                  Size of protein (a.a.)  
 Nucleocapsid  Matrix  Envelope 
HCoV-NL63 377 226 77 
SARS-CoV 422 221 76 
HCoV-OC43 448 230 84 
HCoV-229E 389 225 77 
HKU1 441 223 82 
 
2.1.2 Identification of Transmembrane Regions 
TMHMM Server V.2.0 (Krogh, Larsson et al. 2001) was used to search for 
transmembrane regions in the N, M and E protein sequences, using default settings for 
all algorithms. 
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2.1.3 Hydropathy Predictions 
The hydropathy scores for N, M and E were predicted using the Kyte-Doolittle 
Hydropathy Plots (Kyte and Doolittle 1982); the window size for all amino acids was 
set at default with a window size of 9. This bioinformatics tool determines 
hydrophobic and hydrophilic regions within a protein sequence. 
 
2.1.4 Identification of Proteins Motifs 
The presence of various motifs including N- and O-linked Glycosylation, 
Myriostoylation, Specific Amino acid rich domains (e.g. serine rich domains), Protein 
kinase C phosphorylation and Casein kinase II phosphorylation sites were predicted in 
the HCoV-NL63 proteins using ScanProsite (SIB 2012). ProRule (SIB 2012) was 
used to predict intra-domain features. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Materials and Methods 
 
33 
 
 
2.2   Cloning of genes for expression in an E. coli cell system 
2.2.1 Materials and Reagents 
HCoV-NL63 RNA, used as template to synthesize the 1st strand cDNA, was a kind 
gift from Prof. L van der Hoek, Holland. The RNA had been extracted from a fifth-
passaged virus (strain Amsterdam1), that was obtained from a clinical sample. SARS-
CoV N was a kind gift from Prof Y-J Tan, Singapore. SDS gel preparation kit, DMSO 
and all antibodies were purchased from Sigma Aldrich. All other chemicals were 
purchased from Promega.  
 
2.2.2 Bacterial strains and plasmids 
KRX and JM109 competent cells used in this project were purchased from Promega. 
JM109 competent cells were used for its high transformation efficiency and α-
complementation, thus allowing for blue/white colony selection. On the other hand, 
KRX competent cells were used for transient expression of the recombinant proteins. 
Plasmid vectors used included the pGEM-T Easy Vector (Approximately 3.2 kb), 
which served as a shuttling vector and the pFLEXI vector (Approximately 4.4 kb), 
which was used as the bacterial expression vector. 
 
2.2.3 RT of HCoV-NL63 RNA 
Reverse transcription (RT) was carried out using a mixture of 2μl RNA template (108-
10
9 copies/ml), 1μl of Oligo (dT)15 primer (100μM stock), 1×incubation buffer, 2μl of 
dNTP mix (10mM stock), 20U RNasin® Ribonuclease inhibitor, 15U of AMV 
Reverse Transcriptase and 4μl MgCl2 (25 mM), made up to a final volume of 20μl in 
nuclease-free water, according to the manufacturer’s specifications (Promega). The 
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reaction was then heated at 42ºC for 60 min, 95ºC for 5 min and then cooled to 0ºC 
for 5 min in order to deactivate the enzyme. 
2.2.4 PCR Primer Design 
For ligation into the pFlexi™ protein expression vector, restriction sites had to be 
manually inserted into the gene of interest. For this to be accomplished a SgfI (5´ 
GCGATCGC 3´) restriction-site was incorporated into the forward primer and a PmeI 
(5´ GTTTAAAC 3´) restriction site was incorporated into the reverse primer. The 
addition of a C residue upstream of the ATG in the forward sequence prevented 
frameshifts from occurring in the protein reading frame. Also, four additional 
nucleotides were added to the 5’- and 3’-ends to allow for a more efficient restriction 
digest of the PCR products. Primers for amplification of the N constructs (Table 2.2) 
were designed using sequences obtained from NCBI (the accession number for each 
sequence is shown): SARS-CoV N (AY360146.1) and HCoV-NL63 N (DQ846901.1)  
 
Table 2.2: Forward and Reverse primer sequences for PCR amplification of SARS-
CoV N and HCoV-NL63 N 
Gene Primer Sequence 
SARS-
CoV N 
Forward AGGA GCGATCGC CATGTCTGATAATGGACCCCAAT
CAAACC 
Reverse TTGTGTTTAAACTTATGCCTGAGTTGAATCAGCAGA 
HCoV-
NL63 N 
 
Forward GGGC GCGATCGC CATGGCTAGTGTAAATTGGGCCG 
Reverse ACAGGTTTAAACTTAATGCAAAACCTCGTTGACAAT
TTC 
SgfI restriction site – striated box; PmeI restriction site – dashed line box; ATG start 
codon – Bold; TAA stop codon underlined 
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2.2.5 Polymerase Chain Reaction (PCR) and Purification of the Amplicons 
The PCR reaction was set-up to a final volume of 25 μl which included 0.5 μl dNTP 
mix (0.2 mM), 2.0 μl MgCl2 (1.5 mM), 1 μl for each forward and reverse primer (10 
pmole/ul), 5 μl 5x Green GoTaq Flexi™ buffer, 0.5 μl GoTaq polymerase (5U/μl) and 
2 μl cDNA template (1:10 dilution of original cDNA sample). The annealing 
temperature was set to 60
o
C as it was the lowest temperature at which there was no 
non-specific amplification. The following PCR conditions were used: 95°C for 3 min, 
followed by 30 cycles of 95°C for 1 min, 60°C for 1 min and 72°C for 2min. The final 
elongation was run for 15 min at 72°C. The PCR product was diluted in a ratio of 1:6 
with 6x Blue/Orange loading dye [0.4% (v/v) orange G, 0.03% (v/v) bromophenol 
blue, 0.03% (v/v) xylene cyanol FF, 15% (v/v) Ficoll® 400, 10 mM Tris-HCl (pH 
7.5) and 50 mM EDTA (pH 8.0)]. This mixture was separated by electrophoresis on a 
1% (w/v) agarose gel (containing 0.001% (v/v) ethidium bromide) in TBE [89 mM 
tris (hydroxymethyl) aminomethane, 0.089 mM boric acid, 2 mM EDTA (pH 8)] 
buffer at 90 V for approximately 1 hour. The agarose gel was viewed under short-
wave length UV light. Bands of interest (chosen according to expected size) were 
excised and purified using the Wizard SV Gel and PCR Cleanup System (Promega). 
Briefly, the excised gel pieces were dissolved in 1μl/mg membrane binding solution 
(4.5 M guanidine isothiocyanate and 0.5 M potassium acetate) at 60°C with frequent 
vortexing. The dissolved gel mixture was then transferred to a minicolumn assembly 
and incubated at room temperature for 1 min. The DNA was transferred to the 
minicolumn membrane by centrifugation at 14000 rpm for 1 min. The column was 
washed, first with 700 μl and then with 500 μl, membrane wash solution (10 mM 
potassium acetate, 80% (v/v) ethanol and 16.7 μM EDTA). Next, the columns were 
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centrifuged for 1 min at 14000 rpm to evaporate the residual ethanol present in the 
membrane washing solution. DNA was eluted with 30 μl nuclease free water into a 
clean 1.5 ml Eppendorf tube by centrifugation at 14000 rpm. The purified PCR 
product was then quantified using a Qubit™ 1.0 fluorometer quantification system.  
 
2.2.6 Cloning and Verification of Purified Amplicons 
2.2.6.1 Ligation into pGEM T-Easy Vector 
Next, the purified amplicons were ligated into a pGEM® T-easy shuttling vector 
according to manufacturer’s instructions. This vector allows for easy sequencing of 
the cloned viral genes. Also, the 3’thymine overhangs present in the cloning site of 
the pGEM vector creates ‘sticky ends’ which allow for easy ligation of the amplified 
PCR product; Taq polymerase incorporates a template-independent deoxyadenosine 
residue to the 3’of the amplified fragment. pGEM® also contains a β-galactosidase 
gene which is used for blue/white colony screening. M13 primer recognition sites are 
also present up- and down-stream of the insert allowing for easy sequencing of the 
fragment. The ligation reaction was set up as follows: 5 μl 2X T4 DNA rapid ligation 
buffer, 1 μl pGEM® vector (50 ng), 3 μl gel-purified PCR product and 1 μl T4 DNA 
Ligase (0.5 U). This reaction was then incubated for one hour at 4°C.  
2.2.6.2 Transformation of JM109 E. coli and Screening for Recombinant Clones 
Luria Bertani (LB) media (10 g pancreatic digest of casein or tryptone powder, 5 g 
yeast extract powder and 5 g NaCl per 1 L, pH 7.2) is the most common liquid media 
used in the cultivation of bacteria such as E. coli. The media was sterilized by 
autoclaving, after which 1 μl/ml ampicillin was added. LB agar was prepared by 
additing 15 g bacteriological agar per litre of LB media.  
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JM109 (Promega) competent E. coli cells known for their high transformation 
efficiency was  used in the transformation process according to the manufacturer’s 
protocol, however minor modifications were done in order to obtain optimal results. 
In summary, 50 μl of the competent cells were thawed on ice for about 5 minutes and 
thereafter 5 μl of the ligation reaction was added to the cells, these were then 
incubated on ice for 20 minutes. The cells were then heat-shocked at 42°C for 45 sec 
in a water bath and returned to ice for 2 min. Then, 950 μl of LB medium (without 
ampicillin), pre-warmed to room temperature, was added and incubated at 37°C for 1 
hr 30 min. The cells were then pelleted at 2000 rpm for 10 min and resuspended in 
200 μl of fresh LB media. A spread plate of the cell suspension was done on LB agar 
plates containing 1 µg/ml ampicillin, 0.1 M IPTG and 3% (v/v) X-gal and plates were 
incubated at 37°C for 16hrs. Following the incubation period, the plates were 
screened for white colonies, which were picked with a sterile toothpick. The toothpick 
was first used to inoculate a PCR mix for colony PCR-screening and then dropped 
into a culture-tube containing terrific broth media. The PCR reaction was done as 
described previously, but the initial denaturation temperature was increased to 5 min 
to make sure that the cells were completely lysed and the template strand denatured. 
The cell cultures were incubated at 37
o
C for 14 hours. 
75% glycerol stocks were prepared from overnight cultures confirmed to contain the 
correct insert size by colony PCR. The glycerol stocks were prepared by adding 750 
µl of the cell suspension to 250 µl of glycerol; this was thoroughly mixed and stored 
at -80
o
C for long-term storage. The remaining cell cultures, used for making glycerol 
stocks, were used to extract the plasmid DNA using the SV Mini-Prep kit (Promega). 
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2.2.6.3 Plasmid Extraction (Mini-Prep) 
The mini-prep procedure is used to isolate plasmid DNA from bacterial cells using an 
alkaline lyses method. According to the manufacturer’s protocol it had been advised 
to use 2 ml overnight culture for plasmid isolation however it was found that using a 
biomass (BM) index was more relevant to ensure the highest yield of plasmid DNA. 
Biomass was therefore calculated using the following equation:   
OD600 (mg/ml) x Vol (ml) = BM (mg) 
A biomass of approximately 4 mg was used for all mini-preps. After the cells were 
harvested by centrifugation at 14000 rpm the pellet was resuspended in 250 μl cell 
suspension buffer (50 mM Tris-HCl, 10 mM EDTA) containing 100 ug/ml RNase. 
Cells were then lysed in an alkaline (pH 12) lysis buffer (1% (w/v) SDS, 0.2M 
NaOH) which denatures all DNA to its single stranded form. Plasmid DNA is, 
however, circular and therefore when the pH is neutralized (to pH 7), with the 
addition of 350 μl neutralization buffer (80 mM potassium acetate, 8.3 mM Tris-HCl, 
40 μM EDTA), the plasmid can easily realign, where chromosomal DNA remains in a 
single stranded form and interacts with cellular debris. On centrifugation at 14000 
rpm for 1 min the cellular debris, with bound chromosomal DNA, is pelleted and 
therefore separated from plasmid DNA. The clear lysate is then transferred to a 
minicolumn and plasmid DNA is bound to the silica membrane. Plasmid DNA is then 
washed with 700 μl wash solution by centrifugation at 14000 rpm for 1 min and 
eluted in 50 μl nuclease free water and transferred, by centrifugation at 14000 rpm, to 
a clean 1.5 ml Eppendorf tube. Plasmid DNA is stored at -20°C. 
2.2.6.4 Restriction Endonuclease Digest 
As EcoRI restriction sites are located up- and down-stream from the cloning site, 
removal of the ligated product with these restriction enzymes was performed as a 
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second confirmatory test. The restriction reaction was set up as follows; 2 μl 10x 
buffer H (50 mM Tris-HCl, 10 mM MgCl2, 100 mM NaCl), 0.2 μl BSA (bovine 
serum albumin), 1.0 μl EcoRI and 16.8 μl isolated plasmid, which was incubated at 
37°C for 3 hours in a water bath, following which, the reaction was viewed on a 1% 
(w/v) agarose gel under UV light to confirm the presence of the viral gene.  
2.2.6.5 Nucleotide Sequencing and Sequence Analysis 
Extracted plasmids were sequenced with M13 forward and reverse primers to ensure 
no base pair mutations occurred (Inqaba Biotec). Results were viewed with FinchTV 
(www.geospiza.com) and extracted sequences were aligned using the multiple 
sequence alignment function in ClustalX (Version 2.0.12). Files were subsequently 
exported to GeneDoc (Version 2.7.000) for viewing. 
 
2.2.7 Ligation into Flexi Vector and Transformation of KRX competent E. coli 
2.2.7.1 Restriction with Flexi Enzymes (Sgf1 and Pme1)  
Flexi™ vectors (Appendix 12) contain a barnase gene (a lethal gene) between the 
SgfI and PmeI restriction sites, which prevents the growth of unsuccessfully ligated 
plasmids. This gene must first be removed with Flexi™ restriction enzymes before 
ligation with the viral gene. The barnase gene of the Flexi™ vector and viral gene 
ligated into the pGEM® vector was cut-out according to manufacturer’s instruction. 
Briefly, the restriction reaction to remove the insert from the pGEM® vector was set 
up as follows, 4 μl 5x Flexi™ digest buffer (10 mM Tris HCl pH 7.4), 150 mM KCl, 
50 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.25 mg/ml BSA, 0.05% (w/v) Thesit® 
and 50% (v/v) glycerol), 5 μl (±0.1ug/ul) mini-prep pGEM® vector, 1 μl Flexi™ 
enzyme blend (SgfI and PmeI) and 10 μl nuclease free water was incubated at 37°C 
for 3 hours. The enzyme was then deactivated at 65°C for 20 min. It was noticed that 
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yield was greatly increased when the nuclease free water was replaced with mini-prep 
pGEM® vector and therefore this volume was increased to 15 μl and nuclease free 
water was removed from the reaction. The restriction reaction was run on a 1% (w/v) 
agarose gel electrophoresis with ethidium bromide and viewed under UV light. The 
bands of interest were excised from the gel and gel-purified as previously described.  
2.2.7.2 Ligation into Flexi Vector 
Each insert was ligated into the pFN2A Flexi™ vector according to the 
manufacturer’s instructions. Briefly, 10 μl 2X Flexi™ ligase buffer (60 mM Tris-HCl 
(pH 7.8 at 25°C), 20 mM MgCl2, 20 mM DTT, 2 mM ATP), 5 μl acceptor Flexi™ 
vector (cut with SgfI and PmeI restriction enzymes), 4 μl (±0.1 μg/μl) viral gene 
product (cut with SgfI and PmeI restriction enzymes) and 1 μl T4 DNA ligase (5 U/ 
μl) was incubated at 4°C, overnight. The Flexi™ vector appends a GST fusion protein 
to the N-terminal end of the expressed viral protein. 
2.2.7.3 Transformation of KRX strain with Recombinant Plasmid 
Ligated pFLEXI constructs were transformed into KRX strain of competent E. coli 
(Promega). Briefly, KRX cells were removed from -80°C freezer and thawed on ice, 
to which 5 μl ligation product was added and returned to ice for 10 min. The cells 
were then heat-shocked for 15-20 sec at exactly 42°C and returned to ice for 2 min. 
450 μl LB broth, without ampicillin, was added to each transformation reaction and 
incubated for 60 min at 37°C with shaking at 180 rpm. Following which, cells were 
harvested at 2000 rpm for 10 min and resuspended in 200 μl LB broth, of which 100 
μl was plated on LB plates containing 1 μg/ml ampicillin. Plates were incubated at 
37°C for 16-20 hours. Single colonies were then picked and inoculated into terrific 
broth and corresponding PCR mix. Cultures were incubated at 37°C for 14 hours and 
colony PCR results were used to select cultures with correct insert. Cultures were 
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stored in glycerol stocks at -80°C. If colony PCR was not adequate to identify cultures 
with correct vector construct, the plasmids were isolated using the mini-prep 
technique and constructs were later identified by either PCR or restriction digest using 
SgfI and PmeI restriction enzymes. 
Sequence-verified constructs were used for expression using the KRX cells. Even 
though generating the constructs for expression in a bacterial system formed part of 
this thesis, expression of the proteins were performed as part of a larger project and 
did not form part of the work reported here. However, the work reported in this 
section was included in a publication by Berry and colleagues (Berry 2012). 
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2.3 Expression of proteins in a mammalian cell system 
2.3.1 Bacterial strains and recombinant plasmids 
In this thesis, the DNA constructs used for expression of proteins in COS-7 cells were 
kind gifts from Dr M. Muller, Germany and Prof Y-J Tan, Singapore (Table 2.3); all 
constructs were received as glycerol stock of transformed E. coli cultures. Before 
proceeding to the expression studies, recombinant plasmids were verified for correct 
inserts. Briefly, a loop-full of the respective bacterial glycerol stock was streaked onto 
an LB agar plate and incubated overnight. Thereafter, it was screened for single 
colonies and inoculated into LB media containing ampicillin for 14 hours. Following 
incubation, plasmid DNA was extracted as described in 2.2.6.3.  
 
Table 2.3: Constructs used for expression of proteins in COS-7 cells 
Constructs HA-tagged protein expressed Source 
pCAGGS-N-HA HCoV-NL63 nucleocapsid M. Muller 
pCAGGS-M-HA HCoV-NL63 membrane M. Muller  
pCAGGS-E-HA HCoV-NL63 envelope M. Muller 
pXJ40-GST-HA Glutathione S-transferase (used as positive 
transfection control) 
Y-J Tan 
 
2.3.2. Verification of recombinant plasmid 
2.3.2.1 Restriction Endonuclease Digest 
Following plasmid DNA extraction (section 2.3.1), restriction endonuclease digests 
were used to verify correct insert size. In the case of the pCAGGS constructs, the 
restriction endonucleases used for the digests were EcoR1, the recognition site of 
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which is found upstream from the multiple cloning site, and Not1, the recognition 
sites of which is found downstream from the multiple cloning site. Since EcoR1 
performs optimally in buffer H and Not1 in buffer D, a double digest was performed 
to excise the inserts.  
For the pXJ40 construct, the restriction endonucleases used for the digests were XhoI, 
the recognition site of which is found upstream from the multiple cloning site, and 
BamH1, the recognition sites of which is found downstream from the multiple cloning 
site. Since Xho1 performs optimally in buffer D and BamH1 performs optimally in 
Buffer E, a double digest was performed to excise the inserts. 
The restriction enzyme reactions were set up as follow: 
First digest: 16 μl sterile, deionised water, 2.0 μl 10x Buffer H or D (depending on 
the enzyme used), 1.0 μl acetylated BSA (10 μg/μl), 1.0μl purified plasmid; mixed by 
pipetting, then 1.0 μl EcoR1 or XhoI (10 U/μl) was added in a final reaction volume of 
21 μl. The reaction was then incubated at 37 °C for 2 hours in a water bath, following 
deactivation of the enzyme at 65°C for 15 minutes. The enzymatic digest products 
were purified using the Wizard
®
 SV Gel and PCR Clean-Up System (Promega) to 
remove the small oligonucleotides released by the restriction digest. Briefly, an equal 
volume of 21 μl/mg membrane binding solution (4.5 M guanidine isothiocyanate and 
0.5 M potassium acetate) was added to the reaction tubes and mixed by vortexing. 
The mixture was then transferred to a minicolumn assembly and incubated at room 
temperature for 1 min. First digest reaction mix was transferred to the minicolumn 
membrane by centrifugation at 14000 rpm for 1 min. Electrostatic interactions 
generated in the presence of chaotropic salts allow DNA to bind to the silica 
membrane. The DNA was washed with 700 μl and then 500 μl membrane wash 
solution (10 mM potassium acetate, 80% (v/v) ethanol and 16.7 μM EDTA) by 
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centrifugation at 14000 rpm for 1 and 5 min, respectively. A further 1 min 
centrifugation at 14000 rpm was necessary to ensure complete evaporation of residual 
ethanol. DNA was eluted in 16μl nuclease free water which neutralizes the 
electrostatic interactions releasing the purified DNA from the membrane. The purified 
DNA was transferred to a clean 1.5 ml microcentrifuge tube by centrifugation at 
14000 rpm. 
Second digest: 2.0 μl 10x buffer D or E (depending on the enzyme used), 1.0 μl 
acetylated BSA (10 μg/μl), 1.0μl isolated plasmid; solutions mixed by pipetting, then 
1.0 μl Not1 or BamHI (10 U/μl) was added in a final reaction volume of 21 μl. The 
reaction was incubated at 37°C for 2 hours in a water bath, following deactivation of 
the enzyme at 65°C for 15 minutes. 
2.3.2.2 Electrophoresis of the restriction enzyme digests of plasmids 
The restriction digest products were diluted in a ratio of 1:6 with 6x Blue/Orange 
loading dye (0.4% (v/v) orange G, 0.03% (v/v) bromophenol blue, 0.03% (v/v) xylene 
cyanol FF, 15% (v/v) Ficoll® 400, 10 mM Tris-HCl (pH 7.5) and 50 mM EDTA (pH 
8.0)) and separated on a 1% (w/v) agarose gel (containing 0.001% (v/v) ethidium 
bromide) by electrophoresis in TBE buffer (89 mM tris (hydroxymethyl) 
aminomethane, 0.089 mM boric acid, 2 mM EDTA (pH 8)) at 90 V for approximately 
1 hour. The agarose gel was viewed under short-wave length UV light. 
 
2.3.3 Plasmid purification (Midi-prep) 
The midi-prep procedure is used to isolate high copy plasmid DNA from bacterial 
cells, using a silica-based anion-exchange resin for routine separation of different 
classes of nucleic acids. The manufacturer’s protocol advises using 5-30 ml of 
overnight culture, which is grown at 37°C with vigorous shaking. However, it was 
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found that using a biomass (BM) index was more relevant to ensure the highest yield 
of plasmid DNA. Biomass was therefore calculated using the following equation:  
OD600 (mg/ml) x Vol (ml) = BM (mg) 
A biomass of approximately 4 mg was used for all midi-preps.  
 
Table 2.4: Composition of all the buffers used in this experiment   
Buffer Composition 
Resuspension Buffer S1: 50 mM Tris-HCl, 10 mM EDTA, 100 μg / mL RNase A, 
pH 8.0 
Lysis Buffer S2: • 200 mM NaOH, 1 % SDS 
Neutralization Buffer S3: • 2.8 M KAc, pH 5.1 
Equilibration Buffer N2: 100 mM Tris, 15 % ethanol, 900 mM KCl, 0.15 % Triton 
X-100, adjusted to 
pH 6.3 with H3PO4 
Wash Buffer N3: • 100 mM Tris, 15 % ethanol, 1.15 M KCl, adjusted to pH 
6.3 with H3PO4 
Elution Buffer N5: 100 mM Tris, 15 % ethanol, 1 M KCl, adjusted to pH 8.5 
with H3PO4 
 
 
Cultures were grown overnight (14-16 hrs) in LB broth supplemented with ampicillin 
at 37°C with constant shaking. The cultures were then centrifuged at 6,000 x g for 15 
min at 4°C and the supernatant discarded. The pellet of bacterial cells was 
resuspended in 4ml of Buffer S1 + RNase A. 4mls of Buffer S2 was added to the 
suspension and the tubes were mixed by gently inverting it six–eight times. The 
mixture was then incubated at room temperature (18–25 °C) for 2– 3 min. Then, 4 ml 
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of pre-cooled Buffer S3 (4°C) was added to the suspension. Immediately thereafter, 
the lysates was mixed by gently inverting the flasks six–eight times until a 
homogeneous suspension containing an off-white flocculate was formed. The 
suspension was then incubated on ice for 5 min. A NucleoBond AX 100 (Midi) 
Column was then equilibrated with 2.5 ml of Buffer N2. The column was allowed to 
empty by gravity flow. The flow-through was then discarded. To clear the bacterial 
lysate a folded filter was placed in a funnel of appropriate size. The filter paper was 
wetted using a few drops of buffer N2 and the bacterial lysate was loaded onto the wet 
filter and the flow-through was collected. The cleared lysate was now loaded onto the 
NucleoBond® Column. The column was allowed to empty by gravity flow. 
Following this, the column was washed with 10 ml of buffer N3 and the flow-through 
discarded. The plasmid DNA was then eluted with 5 ml of Buffer N5. 3.5 ml of room-
temperature isopropanol was then added to precipitate the eluted plasmid DNA. It was 
mixed carefully and centrifuged at ≥ 15,000 x g for 30 min at 4 °C. The supernatant 
was then carefully discarded. The pellet was then washed and dried by adding 2 ml of 
room temperature 70% ethanol to the pellet and resuspended by briefly vortexing. It 
was then centrifuged at ≥ 15,000 x g for 10 min at room temperature (18–25 °C). All 
the ethanol was carefully removed from the tube using a pipette tip. The pellet was 
then allowed to dry at room temperature for 5-10 mins. The DNA was finally 
reconstituted by dissolving the pellet in 1ml of sterile deionized H2O under constant 
spinning for 10-60 min. The resuspended DNA was stored at - 20°C until further use. 
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2.3.4 Quantification of plasmids by means of fluorometry 
The plasmid yield was quantified using the Qubit Fluorometer according to 
Invitrogen’s protocol and application guide for the QubitTM DNA assay.  
2.3.5 Verification of plasmid constructs by means of restriction endonuclease 
digestion 
The plasmids veracity was confirmed by means of restriction enzyme digest using the 
same enzymes and method as described earlier. Electrophoresis was carried out on a 
1% agarose gel at 90 V for 90 minutes to confirm whether the correct plasmid 
constructs were present. 
 
2.3.6 Nucleotide sequencing and sequence analysis 
Extracted plasmids were sequenced with M13 reverse primers to ensure no base-pair 
mutations occurred (Inqaba Biotecnology). Results were viewed with FinchTV 
(www.geospiza.com) and extracted sequences were aligned using the multiple 
sequence alignment function in ClustalX (Version 2.0.12). Files were subsequently 
extracted to GeneDoc (Version 2.7.000) for viewing. 
 
2.3.7 Mammalian Cell Culture 
Cos7 cells (African Green Monkey Cercopithecus aethiops Fibroblast-like Kidney 
Cells) were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) 
supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 1% glutamine 
and 1% penicillin/streptomycin (Sigma-Aldrich). The cells were incubated in a 37°C 
incubator with 5% CO2. Adherently growing cells attach themselves to the surface of 
the culture plate and each other. This is made possible by surface proteins acting as 
bridges to dissociate cells from the culture flasks or dishes and each other, these 
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protein bridges must be broken. Trypsin is a digestive enzyme, able to break the 
protein connections between cells and culture surfaces. Trypsinization is used for 
passaging cells and to obtain a suspension for further analysis. The cells were 
passaged every 2-3 days by means of Trypsinization as follows: the media was 
removed from the flask, the adherent cells were then rinsed 3 times with pre-heated 
PBS solution. 1-2 mls of Trypsin-Versene EDTA (5%) was added and incubated for 
3-5 minutes at 37°C. The cell layer was detached by tapping on the surface of the 
flask. Then, 2 volumes of serum-containing media were added to the flask to stop 
trypsinization. The cells were dissociated by pipetting the suspension gently up and 
down. Next, the cells were transferred into a centrifuge tube and then centrifuged at 
500 x g for 5-10 minutes. The supernatant was carefully removed using a pipette and 
the cells were resuspended in the culture media prepared as above. 
 
2.3.8 Transfection of COS-7 cells 
2.3.8.1 Trypan blue dye exclusion 
The cells were first trypsinated to dissociate it. Next, 10μl of the cells were diluted in 
90 μl of PBS (for the best results 5 x 105 cells/ml were re-suspensed in PBS). 100 μl 
of the cell suspension was transferred to a clean 1.5 ml eppendorf tube and gently 
mixed in an equal volume of 0.2% trypan blue solution in PBS. It was the incubated 
for 3 minutes at room temperature.  
2.3.8.2 Cell counting with a hemocytometer (Neubauer chamber) 
The counting chamber was thoroughly cleaned and covered with a new coverslip. 10 
μl Trypan blue stained cell suspension was withdrawn and loaded to the chamber by 
applying the suspension to the slit between the base and coverslip; the chamber fills 
by means of capillary action. Under the microscope, the number of viable and non-
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viable (stained) cells was counted immediately in 4 large quadrants. The arithmetic 
mean of the 4 quadrants was calculated and the value was multiplied by 2 x 10
4
 to 
obtain the concentration (cells/ml) in the unstained cell suspension prepared as above. 
The cell viability was calculated as: Viable cell count/ total cell count x 100.  
2.3.8.3 Seeding of cells 
After the cells were counted, it was seeded in a 6 well plate at a concentration of 5 x 
10
5 
cells per well. This was then incubated overnight in complete cell culture media 
without any antibiotics, as this could cause cell death during transfection. 
2.3.8.4 Transfection of Cos 7 cells with N-, M-, E-HA and the negative control 
GST-HA 
When the cells were 80-90% confluent, the transfection experiments were conducted 
using Lipofectamine 2000 (Invitrogen). One hour before the transfection process, the 
media was removed from the seeded cells and 2 ml of fresh media was added 
(DMEM+FBS only) and incubated. Next, 4 μg of the N, M and E constructs and 1 μg 
of the positive control was used for transfection. The appropriate amount of the viral 
DNA construct or positive control was added to 100 μl of Opti-M medium 
(Invitrogen), respectively. In another microcentrifuge tube, 12 μl of Lipofectamine 
2000 was added to 100 μl of Opti M (per construct to be transfected). Both mixtures 
were then incubated for 5 min at room temperature. Following incubation the 
construct-Opti-M mixture was added to the Lipofectamine-Opti-M mixture and 
incubated for 20 min at room temperature. The mixtures of DNA and lipofectamine 
were then added dropwise to the respective labelled wells. The media was changed 4-
6 hrs post transfection with fresh complete medium and incubated for 24 hours before 
lysing the cells.  
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2.3.8.5 Cell lysis 
After the 24 hour incubation period, the cells were harvested by adding ice cold PBS 
to the wells and scraping them off with a cell scraper. Dislodged cells were 
transferred to a 15 ml Greiner tube; this process was done three times in order to 
transfer as much of the cells from the wells to the tubes. The cells were then 
centrifuged at 3000 x g for 5mins and the supernatant discarded. Cell pellets were re-
suspended in 1ml ice cold PBS to wash off the excess culture media and centrifuged 
at 3000 x g for 5 mins again and the supernatant was discarded. The cells were 
resuspended once again in 1ml ice cold PBS and transferred to a clean 1.5 ml 
Eppendorf tube. Following centrifugation, cell pellets were resuspended by vortexing 
in 2 ml/g lysis buffer (20 mM Tris-Cl pH 8, 200 mM NaCl, 1 mM EDTA pH 8 and 
0.5% Triton X- 100) containing a protease inhibitor cocktail (Invitrogen) for 
mammalian cells (Table 2.4 summarises the various functions of the components of 
this lysis buffer). The cells were then incubated on ice for 20 mins and thereafter 
centrifuged at full speed to pellet the membranous part of the cell which does not 
contain the proteins of interest and the supernatant was collected and stored @ -70°C.  
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Table 2.5: Functions of components of chosen cell lysis buffer 
Compound Function 
TritonX Non-ionic detergent; improves solubility of 
GST fusion proteins and prevents 
aggregation of lysed cells. 
NaCl Provides an osmotic shock to cells 
Tris Interacts with lipopolysaccharides in the 
outer membrane of the cell and thereby 
increases permeability. 
EDTA Inhibits divalent cation-dependent proteases 
 
2.3.9 Protein Expression Analysis 
2.3.9.1 Cell Lysate Preparation  
The lysates were then prepared in order to run on a SDS-PAGE gel. Equal volumes 
(1:1) of the lysates and Laemmli blue loading dye (4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromophenol blue and 0.125 M Tris HCl) was mixed in an 
Eppendorf tube. The samples were then boiled at 98°C for 2 min, except for the M 
protein which is boiled at 50°C for 10 min.  
2.3.9.2 SDS-PAGE 
A 3% stacking and a 15% separation SDS-PAGE gel was used to separate proteins in 
using a Biorad system. Electrophoresis was done at 15 mA/gel for 80 mins in Tris-
glycine SDS running buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS (pH 
8.3)) The SDS-PAGE gel was then transferred to a Western Blot. 
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2.3.9.3 Western Blot Analysis 
For Western Blots, the proteins, separated by SDS-PAGE, were transferred to a 
nitrocellulose or PVDF membrane, where neither membrane had any noticeable 
preferential properties. Prior to transfer the nitrocellulose membrane was equilibrated 
in 20% (v/v) methanol and the PVDF in 100% (v/v) methanol. Proteins were 
transferred in transfer buffer (27 mM tris(hydroxymethyl)-amino-methane, 191 mM 
glycine and 20% (v/v) methanol) in a submersion system at 100 V for 90 min, after 
which, the membrane was blocked with a 5% (w/v) milk and 0.05% (v/v) tween 20 in 
PBS solution for 30 min on a rocker. The membrane was then incubated at 4°C 
overnight on a roller in 3% (w/v) milk and 0.05% (v/v) Tween 20 in PBS solution 
with the primary antibody, rabbitα HA, in a dilution of 1:250. The membrane was 
then washed in a wash solution (0.05% (v/v) Tween 20 in PBS) for 1 hour. The 
secondary 
antibody, peroxidase-labeled goatαrabbit, was added in a dilution of 1:1000 in fresh 
solution previously described and incubated at room temperature for 1 hour on a 
roller, following which, the membrane was washed in wash solution with subsequent 
addition of the peroxidase substrate. The presence of the GST-fusion protein was 
determined by colorimetric analysis using 3,3’,5,5’ Tetramethylbenzidine (TMB) 
liquid substrate system for membranes (Sigma-Aldrich). 
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3. Results and Discussion 
3.1. Bioinformatic Analysis of HCoV-NL63 Nucleocapsid, Matrix and Envelope 
Proteins 
The advancement in genome sequencing technology has brought about a sharp rise in 
genome databases and the rate at which these genomes are sequenced, by far exceeds 
our ability to determine the functions of the proteins which they encode. With the help 
of in silico analysis, researchers are able to predict certain functions of a protein based 
on the biochemical or physiochemical properties of their amino acid sequence. 
However, these predictions should be verified experimentally. 
3.1.1 Multiple sequence alignment 
Clustal X was used to compare the amino acid sequences of the N, M and E proteins 
of HCoV-NL63 and the other human coronaviruses (Table 3.1). The selected HCoV-
NL63 structural protein sequences (N, M and E) were shown to be most similar to 
HCoV-229E N, M and E (44%-63% a.a. identity; 63%-77% a.a. similarity). This is 
not an unforeseen result, since HCoV-NL63 and HCoV-229E have evolved from a 
most recent common ancestor in the 11
th
 century (Pyrc, Dijkman et al. 2006). The 
high a.a. sequence identities and similarities calculated for the structural proteins, 
provide evidence that their structure and function have been well conserved through 
evolution. 
In Figure 3.1, a comparative analysis of the 5 human coronavirus nucleocapsids, 
identified a conserved 8 amino acid region between amino acids 128-135, this result is 
in contrast to results obtained by Xing et al (2007), that had identified the region of 
amino acids 78-85 within N protein probably was the conserved region for all 
coronaviruses identified so far including HCoV-NL63. Also, multiple small conserved 
regions of 4-5 a.a.’s were observed for the M homologues (Figure 3.2). Although the 
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functions of these conserved regions have not yet been clearly defined, the conserved 
a.a. region in the HCoV-NL63 N protein (FYYLGTGP) may be involved in RNA 
binding (Chang, Hsu et al. 2009; Berry 2012) (Chang et al., 2009). Berry et al had 
seen that at these long stretches of conserved amino acid regions found within the N 
protein are in fact regions of disorder and according to Chang et al. all disordered 
regions found within the SARS CoV N protein are also capable of binding to RNA, 
although the RNA binding domains in the N protein have been previously linked to 
the N-terminal domain (NTD) and the C-terminal domain (CTD) respectively (Chang, 
Hsu et al. 2009) . 
 In contrast to the N and M proteins, the E protein (Figure 3.3) does not show as much 
sequence identity with some of the viruses in this study group although the percentage 
similarity with other coronavirus species is high (Table 3.1). When the percentage 
sequence homology is high, this could be an indication that these viruses share the 
same topology of the E-protein than others and seeing that the highest percentage 
homology is with 229E, which forms part of the same group as NL63, this brings 
about an indication that coronaviruses from the same groups could potentially share 
the same E protein topology?  
This is also an indication that E proteins characteristics are not conserved amongst 
nidoviruses. This makes sense as different topologies for the E protein has been 
observed, thus bringing about different functions for the E protein. Potential roles for 
E in assembly have been previously observed, such as helping to bend membranes or 
playing a role in membrane scission by its hairpin formation topology (Ruch and 
Machamer 2012). The efficient trafficking of virions through secretory pathway could 
be due to a function that may be related to its transmembrane domains forming ion 
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channels (DeDiego, Alvarez et al. 2007; Ruch and Machamer 2012; Ruch and 
Machamer 2012).  
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Table 3.1: Multiple sequence alignment. Comparison of HCoV-NL63 N, M and E 
amino acid sequences to homologues from selected coronavirus isolates. Identity 
values (%) are shown in BOLD and similarity values (%) are shown in ITALICS. 
% Amino Acid Homology 
HCoV-NL63 
structural proteins 
 HCoV-
229E 
HCoV-OC43 HKU1 SARS 
N  44 
63 
36 
55 
33 
49 
31 
46 
M  63 
77 
36 
60 
33 
58 
32 
55 
E  47 
72 
44 
48 
29 
56 
18 
48 
To identify homologues, the amino acid sequences of HCoV-NL63 N, M and E was 
compared to sequences in the GenBank database at the National Centre for 
Biotechnology by using the Basic Blast Search Server (Altschul et al., 1990). 
Subsequently, HCoV-NL63 N, M and E was aligned with selected coronavirus N, M 
and E proteins with CLUSTAL X version 2 (Larkin et al., 2007). The sequences 
aligned, with Genbank accession numbers in bold, were: HCoV-NL63 N 
(YP_003771.1), M (YP_003770.1), E (YP_003769.1); HCoV-229E N 
(NP_073556.1), M (NP_073555.1), E (NP_073554.1); HCoV-OC43 N 
(NP_937954.1), M (NP_937953.1), E (NP_937952.1); HKU1 N (YP_173242.1), M 
(YP_173241.1), E (YP_173240.1); SARS-CoV N (AFR58751.1), M (AF58746.1) and 
E (AFR58745.1). 
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Figure 3.1: Multiple sequence alignment of various human coronavirus 
nucleocapsid (N) proteins. Selected HCoV-NL63 N-homologues were aligned 
with CLUSTAL X version 2.0 (Larkin et al. 2007) and viewed with GENEDOC 
version 2.6.002 software (Nicholas et al; 1997). Shading indicates conserved 
regions and gaps were introduced to align sequences. Conserved region larger 
than 5 a.a.’s identified: (i) FYYLGTGP. N amino acid sequences were obtained 
from NCBI (accession numbers in brackets): HCoV-NL63 (YP_003771.1), 
HCoV-229E (NP_073556.1), HCoV-OC43 (NP_937954.1), HKU1 
(YP_173242.1) and SARS-CoV (AFR58751.1). 
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Figure 3.2: Multiple sequence alignment of various human 
coronavirus membrane (M) proteins. Selected HCoV-NL63 M-
homologues were aligned with CLUSTAL X version 2.0 (Larkin et al. 
2007) and viewed with GENEDOC version 2.6.002 software (Nicholas et 
al; 1997). Multiple Conserved regions identified: (i)(ii)(iii)(iv)(v).M 
amino acid sequences were obtained from NCBI (accession numbers in 
brackets): HCoV-NL63 M (YP_003770.1), HCoV-229E M 
(NP_073555.1), HCoV-OC43 M (NP_937953.1), HKU1 M 
(YP_173241.1), SARS-CoV M (AFR58746.1). 
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Figure 3.3: Multiple sequence alignment of various human 
coronavirus envelope (E) proteins. Selected HCoV-NL63 E-
homologues were aligned with CLUSTAL X version 2.0 (Larkin et al. 
2007) and viewed with GENEDOC version 2.6.002 software (Nicholas et 
al; 1997). E amino acid sequences were obtained from NCBI (accession 
numbers in brackets): HCoV-NL63 E (YP_003769.1); HCoV-229E E 
(NP_073554.1); HCoV-OC43 E (NP_937952.1); HKU1 E 
(YP_173240.1); SARS-CoV E (AFR58745.1). 
 
3.1.2 Transmembrane Domains and Hydropathy Plots of HCoV-NL63 N, M and 
E proteins 
Proteins are amino acids that are held together by peptide bonds. Each amino acid has 
a specific “R” group that is unique to it. These groups determine whether proteins are 
hydrophilic (water-loving) or hydrophobic (water-fearing). The hydrophobicity of an 
amino acid would determine where the amino acid would be located in the final 
structure of the protein (Kyte and Doolittle., 1982). In globular proteins the 
hydrophobic R group will be located on the inside of the protein, thus causing it not to 
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be in contact with water in the cytosol. The hydrophilic R groups are located on the 
outside of the proteins, thereby interacting with the water in the cytosol. This 
information can give us an indication on the structure of the proteins. One of the basic 
tenants of biology is that the structure of a protein defines its function. So, being able 
to make predictions about the structure of the HCoV-NL63 structural proteins, could 
enable us to find out more about how these proteins function, which could aid in 
understanding the virus better. A hydropathy plot predicts potential transmembrane or 
surface regions in proteins (Kyte and Doolittle., 1982). 
The Kyte-Doolittle plot works as follows: each amino acid is given a hydrophobicity 
score (Appendix 6) between 4.6 and -4.6. A score of 4.6 is the most hydrophobic and 
-4.6 are the most hydrophilic. A window size needs to be determined in order for 
these scores to show its effect; this window size is determined by the number of 
amino acids whose hydrophobicity scores will be averaged and assigned to the first 
amino acid in the window. Then, the computer program moves down one amino acid 
and calculates the average of all the hydrophobicity scores in that window, thereafter 
the computer program moves down another amino acid and in doing this the average 
of all the hydrophobicity scores is calculated in the second window. This pattern will 
continue until the entire amino acid sequence is screened and the average score for 
each window is assigned to the first amino acid in that window. The default window 
size in this bioinformatics tool is 9 amino acids. The averages are then plotted on a 
graph, with the y-axis  
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Figure 3.4: Comparisons of Transmembrane regions with hydropathy 
predictions of HCoV-NL63 N protein. (A)TMHMM plot indicating 
transmembrane regions in the Nucleocapsid protein sequence. No 
transmembrane domains are present as expected as the N protein is not a 
membrane protein. (B) Kyte-Doolittle Plot indicating the hydrophobic region of 
the Nucleocapsid protein, peaks above 1.9 (the red line) indicates hydrophobic 
regions. 1 false positive peak is shown. 
 
For HCoV-NL63 N, the hydropathy plot (Figure 3.4. A), indicated that the protein is 
strongly hydrophilic and not found within the lipid bilayer of the membrane; most of 
the peaks shown were below 1.6 score. The results obtained for the N protein was 
used as a “negative control”, when compared to the M and E proteins of HCoV-NL63. 
The one peak seen on Figure 3.4 (A) between amino acid numbers 150-200, was 
indicative of a false positive result. TMHMM server V.2.0 (Krogh et al., 2001) was 
also used to search for transmembrane regions in the N protein sequence (Figure 3.4 
A 
B 
A 
B 
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B). As expected, since N is not an integral viral protein, no such regions were 
predicted. 
 
 
 
 
Figure 3.5: Comparisons of Transmembrane regions with 
Hydropathy predictions of HCoV-NL63 M protein. (A) Kyte-Doolittle 
Plot indicating the hydrophobic region of the Membrane protein, peaks 
above 1.9 (the red line) indicates hydrophobic regions. (B) TMHMM plot 
indicating transmembrane regions in the Membrane protein sequence 
 
For the HCoV-NL63 M, four predicted transmembrane regions were seen on the 
TMHMM plot (Figure 3.5 B), found at a.a. positions 20-38, 43-65, 75-97 and 129-. 
A 
B 
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These results were confirmed by the hydropathy plot results (Figure 3.5 A) as it 
corresponded to the hydrophobic peaks on the plot. According to Kyte and Doolittle 
(1982) these hydrophobic peaks could also indicate transmembrane regions. These 
results from our analysis corresponded to an earlier report (M. Muller,2009), but 
contradicted other reports that predicted three transmembrane spanning regions for the 
HCoV-NL63 M (Rottier, Brandenburg et al. 1984; Rottier, Brandenburg et al. 1984; 
Masters 2006; Ye and Hogue 2007; Ruch and Machamer 2012). These differences 
could be due to different Algorithms used in these bioinformatics tools. When I 
changed the algorithms the amount of transmembrane domains changed aswell, 
however the Kyte-Doolittle plot confirms the results I had obtained with the 
Transmembrane domain finder as Kyte and Doolittle (1982) explains how 
hydrophobic regions could possibly be an indication of transmembrane domains (Kyte 
and Doolittle 1982). This makes sense as these domains are not exposed to water in 
the cytosol.  
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Figure 3.6: Comparisons of Transmembrane regions with 
Hydropathy predictions of HCoV-NL63 E protein. (A) Kyte-Doolittle 
Plot indicating the hydrophobic region of the Envelope protein, peaks 
above 1.9 (the red line) indicates hydrophobic regions. (B) TMHMM plot 
indicating transmembrane regions in the Envelope protein sequence. 
 
 
In Figure 3.6A, one very large predicted transmembrane region was seen on the plot 
spanning a.a. position 10-32. This result was confirmed by the hydropathy plot 
(Figure 3.6B) which also predicted a strong positive peak at position 10-35. This 
characteristic formation of the E protein is one of the topologies seen in coronavirus E 
proteins. It is proposed that when the E protein has this topology, it functions as an 
ion channel (Torres, Parthasarathy et al. 2006; Yuan, Liao et al. 2006; Torres, 
Maheswari et al. 2007; Ye and Hogue 2007). However, due to the E protein only 
B 
A 
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having a single hydrophobic domain, it would require oligomerization in order to 
form an ion channel (Ruch and Machamer 2012). Many other studies suggest an 
important role for the ion channel activity of the E protein (Wilson, McKinlay et al. 
2004; Liao, Yuan et al. 2006; Torres, Parthasarathy et al. 2006; Wilson, Gage et al. 
2006; Torres, Maheswari et al. 2007); however the role of this characteristic of the E 
protein in infection is not entirely clear. Literature even suggests that this putative ion 
channel activity can be linked with virus replication and release (Ruch and Machamer 
2012) . The M and E proteins of coronaviruses play a vital role in viral assembly and 
some literature even indicate that only M and E is needed for viral assembly 
(Vennema, Godeke et al. 1996; Ho, Lin et al. 2004; Yuan, Liao et al. 2006). 
Therefore, using bioinformatics plots to determine the structure of these proteins, 
could aid in predicting the possible functions of these proteins in the virus life cycle. 
Figures 3.7 and 3.8 summarise the membrane topology of M and E as predicted by the 
in silico analysis.  
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Figure 3.7: Illustration of the topology of HCoV-NL63 M protein. 
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Figure 3.8: Illustration of the topology of HCoV-NL63 Envelope protein. 
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Table 3.2: Comparison of various motifs of HCoV-NL63 Proteins N, M and E 
Viral Proteins Nucleocapsid Membrane Envelope 
No. Amino Acids [size 
in kDa] 
377 aa 226 aa 77 aa 
No. Transmembrane 
domains 
(position) 
 4 1 
No. N-linked 
glycosylation sites 
(position) 
7 
(110-113)(145-
148)(146-149)(158-
161)(179-182)(200-
203)(352-355) 
3 
(3-6)(19-22)(188-191) 
 
No. Myristoylation 
sites 
(position) 
 2 
(46-51)(139-144) 
1 
(10-15) 
No. Protein kinase C 
phosphorylation sites 
(position) 
9 
(29-31)(147-149)(151-
153)(155-157)(163-
165)(167-169)(212-
214)(307-309)(334-
336) 
2 
(99-101)(217-219) 
 
No. Casein kinase II 
phosphorylation sites 
(position) 
7 
(136-139)(174-
177)(181-184)(241-
244)(294-297)(334-
337)(354-357) 
3 
(63-66)(186-189)(217-
220) 
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Almost all proteins analyzed to date are post-translational modified. The function of a 
modified protein is often strongly affected by these modifications and therefore, 
increased knowledge about the potential post-translational modifications of a target 
protein may increase our understanding of the molecular processes in which the 
protein plays part (SIB 2012). By using bioinformatic tools, researchers are able to 
identify domains and motifs found in protein sequences, which can then be used to 
predict the structure and possible functions of the proteins. Domains are defined as 
specific combinations of secondary structures that are organized into a characteristic 
three-dimensional structure or fold. Motifs on the other hand, are short sequences (≤ 
20 amino acids) of biological interest (SIB 2012). In Table 3.2, various putative 
domains and motifs were identified in the HCoV-NL63 N, M and E sequences; some 
of these are conserved amongst nidoviruses and others are specific to HCoV-NL63.  
For N, a serine rich domain was predicted at position (144-211). Coronavirus N 
proteins have a high (7 to 11%) serine content forming a serine rich domain; serines 
are potential targets for phosphorylation (Peng, Lee et al. 2008). Between the 
functional C-terminal domain and the N-terminal domain, (CTD and NTD), is a 
segment containing several arginine/ serine (RS) dipeptides that is structurally 
flexible. It is proposed that this RS-rich motif is able to affect a multitude of cellular 
signalling processes, an attribute of cellular precursor mRNA (pre-mRNA) splicing 
factors known as SR proteins (Graveley 2000). The RS domain is phosphorylated 
with dynamism by several SR protein specific kinases, such as those belonging to the 
SR protein kinase (SRPK) and Clk families (Stojdl and Bell 1999; Peng, Lee et al. 
2008). It has been shown that the phosphorylation of the RS domain modulates the 
activity, protein–protein interactions and subcellular localization of SR proteins 
(Graveley 2000). Coronavirus N proteins are phosphorylated in host cells transiently 
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expressing N, as well as virions (Wootton, Rowland et al. 2002; Chen, Gill et al. 
2005; White, Yi et al. 2007). Phosphorylation affects the RNA binding specificity and 
the nucleocytoplasmic shuttling of the N proteins (Chen, Gill et al. 2005; Surjit, 
Kumar et al. 2005). 
In our analysis, the N protein was also found to be extensively N- glycosylated on the 
N terminal. Glycosylation is described as the attachment of a glycan group to a 
residue of the protein (SIB 2012), thus providing it with a hydrophilic cover on its 
outer surface. This is evident as the N protein shows strong hydrophilic tendencies 
when viewed on the Hydropathy plot (Fig 3.4). A previous study had indicated that 
glycosylation of coronaviral proteins is not required for virus assembly, however the 
oligosaccharides could potentially be involved in the virus-host interaction (de Haan, 
de Wit et al. 2003). A study done on HIV-1 had shown that N-linked glycosylation of 
viral proteins provided new insight into the mechanisms that HIV-1 uses to escape 
protective immune responses (Huang, Chou et al. 2008). The HCoV-NL63 N protein 
is N-linked glycosylated at positions (110-113), (145-148), (146-149), (158-161), 
(179-182), (200-203) and (352-355).  
Various putative protein kinase C phosphorylation sites were predicted for N at 
positions (29-31), (147-149), (151-153), (155-157), (163-165), (167-169), (212-214), 
(307-309), (334-336) and casein kinase II phosphorylation at positions (136-139), 
(174-177), (181-184), (241-244), (294-297), (334-337) and (354-357). 
Phosphorylation is one of the most common post-translation modifications that play a 
significant regulatory role in modulating protein functions. The coronavirus N protein 
is highly phosphorylated and it is speculated that this modification has an important 
role in the regulation of coronavirus N protein (White, Yi et al. 2007).  A study done 
by Wisniewski et al (1999) had indicated that phosphorylation of proteins by casein 
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kinase II alters their conformation, stability, and DNA binding specificity 
(Wisniewski, Szewczuk et al. 1999) .   
The M protein of HCoV-NL63 is 226 aa in length. In this study, M was shown to be 
N-glycosylated at amino acids (3-6), (19-22) and (188-191). It also contained putative 
protein kinase C phosphorylation sites at positions (99-101) and (217-219), as well as 
casein kinase II phosphorylation sites at amino acid positions (63-66), (186-189) and 
(217-220). The M and E proteins were predicted to be myrostoilated at positions (10-
15) for E and (46-51) and (139-144) for M, respectively. The N protein, however, was 
predicted not to be myrostoilated, which suggested that this is be unique to intergral 
membrane proteins. These myrostoilation sites were present more or less at the same 
position of the transmembrane domains. Myristoylation is the covalent binding of a 
lipid moiety to the protein, i.e. a myristate group attached through an amide bond to 
the N-terminal glycine residue of the mature form of a protein or to an internal lysine 
residue (Maurer-Stroh and Eisenhaber 2004; SIB 2012). The myristate can also be 
attached through a thio-ester bond to an internal cysteine (Maurer-Stroh and 
Eisenhaber 2004; SIB 2012).  
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3.2. Molecular Cloning of HCoV-NL63 N Protein for Expression in Bacterial 
Cells 
3.2.1. PCR 
The gene of interest (N-gene) was amplified from the 1
st
 copy DNA with gene 
specific primers for unidirectional cloning into the vectors. Primers were designed to 
append the SgfI and PmeI (pFLEXI) restriction enzyme sites to the amplification 
products. These pFlexi restriction endonucleases infrequently causes restriction of 
human and other organisms cDNA (98%). The Sgf1 restriction site is upstream of the 
promoter of the protein coding region. This enables the expression of N-terminally 
tagged and untagged proteins. The Pme1 site contains the terminator sequence for the 
protein coding region, and adds a Valine residue to the carboxy terminus. These 
enzyme cut sites prevent frameshifts from occurring by maintaining the reading frame 
and orientation of the inserts. The amplified N protein of SARS-CoV and HCoV-
NL63 was separated on a 1% Agarose gel (Fig.3.9) by electrophoresis. The 
amplification product for HCoV-NL63 N gene was shown to be ±1100bp and SARS-
CoV N was indicated to be  ±1200 bp in size this corresponds to the gene sizes, 
determined by the accession number from NCBI, for  SARS-CoV N: 1269bp and 
HCoV-NL63 N: 1134bp.  
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Figure 3.9: PCR amplification of viral genes using primers described in 
Table 2.2. Lane M: 100bp marker. Lane 1: SARS-CoV N-gene (±1200bp) 
amplified from pXJHA40 vector; Lane 2: HCoV-NL63 full length N-gene 
(±1100bp). Negative controls (water blanks) were done for all PCR’s and 
remained clear.    
 
        
Once the N gene amplification products were identified the bands representing the 
target genes were excised from the gel for purification with a PCR Gel Clean-Up kit 
(Promega). The viral genes were then ligated into the pGEM vector and used to 
transform JM109 competent E.coli.  
 
3.2.2. EcoRI Digest of pGEM-N 
As a second confirmatory step, prior to sequencing, the insert was removed from the 
vector with the use of EcoRI restriction enzyme (Figure 3.10). EcoRI recognition sites are 
located up- and down-stream of the multiple cloning site, allowing for easy removal of 
the insert. The electrophoresis of the restriction digest of pGEM® vector had confirmed 
SARS-CoV N HCoV-NL63 N  
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that the ligation was successful as indicated by the bands of interest present in Fig 3.10 
HCoV-NL63 N gene is relatively large in size ( ± 1100 bp), thus making it quite hard to 
successfully ligate. The size of the N gene obtained in Fig 3.10 was approximately 
1200bp in length for HCoV-NL63 which corresponds to the expected sizes obtained from 
NCBI (1134bp). The sequencing results (Appendix 1 & 2) had confirmed this successful 
ligation as the nucleotide and deduced amino acid sequences obtained were compared 
against the entries in the Genbank database with respectively the BLAST-N and BLAST-
P programmes (Altschul, Madden et al. 1997), these bioinformatics programmes are 
available on the National Centre for Biotechnology Information web page 
(http://www.ncbi.nlm.nih.gov/BLAST).  
When the insert is ligated correctly into the vector, it closes the loop of the vector and 
changes it into a circular plasmid. This form is essential to the introduction of DNA into 
cells in the transformation step (Bolivar 1978) .  
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Figure 3.10 : Confirmation of successful ligation by restriction of the pGEM® vector with EcoRI 
enzymes. Lane M - 1Kbp molecular marker, lane1-NL-63 N gene Full length sample(S)1, lane2-NL63 
N gene full length S2, lane3-NL63 N gene full length S3, lane4-NL63 N gene full length S4. The 
presence of the correct gene sizes is a second indication of successful ligation and transformation. 
 
3.2.3 SgfI and PmeI digest of pGEM-N recombinants 
The plasmid DNA was enzyme digested with Sgf1 and Pme1 to release the gene of 
interest (Fig 3.11) from the pGEM vector in order for it to be gel purified using the 
Wizard SV gel and PCR purification kit (Promega), it was then subsequently ligated 
into the compatible sites of the pFlexi vector for expression, generating pFlexi-N. 
These recombinant constructs (pFLEXI-N-GST) was then transformed into KRX 
E.coli cells and plated on LB agar plates containing ampicillin. 
S1 S2 S3 S4 
 
 
Vector 
± 3kb 
N-gene 
±1200bp 
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Figure 3.11: Restriction enzyme digest of pGEM vector recombinants with 
pFlexi enzymes SgfI and PmeI. Lane M: 100bp marker; Lane 1: SARS-CoV N 
gene (±1200 bp) and Lane 2: HCoV-NL63 N gene (± 1100bp). Top band is the 
pGEM vector and the bottom band is the gene of interest that was released from the 
vector by the pFLEXI restriction enzymes.  
 
 
3.2.4. Colony PCR of KRX Competent E. coli 
All the transformed colonies formed should be an indication of successful ligation of 
the target gene into the pFLEXI vector. This vector contains a lethal barnase gene 
which would have been replaced by the N gene preventing its activation, which would 
have resulted in no colonies being produced. The pFLEXI vector was especially 
designed to express amino terminal GST-fusion proteins in bacteria. The GST tag can 
be used for detection and purification of expressed proteins. Cleavage of the GST tag 
from the expressed proteins is also made possible by the action of TEV proteases. In 
order for these proteins to be expressed, this vector needs a competent E.coli strain 
that expresses T7 RNA polymerase; therefore the KRX strain was selected.  
The successful cloning of the exact protein coding region into the vector (pFLEXI) 
was verified by means of colony selection and colony PCR subsequent to 
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transformation into KRX competent cells. Figure 3.12 indicates the successful 
transformation of the nucleocapsid genes into KRX competent cells. The bands 
produced in both Fig 3.12 A and B is a clear indication that the genes of interest being 
HCoV-NL63 N and SARS-CoV N were successfully cloned for the expression of its 
respective proteins in a bacterial cell system.  
Sequence-verified constructs had been used for expression with the KRX cells. Even 
though the process of  generating the constructs for expression in a bacterial system 
formed part of this thesis, expression of the proteins were performed as part of a 
larger project and unfortunately did not form part of the work reported here. However, 
the work reported in this section was included in a publication by Berry and 
colleagues (Berry 2012). 
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Figure 3.12: Colony PCR of KRX competent E. coli previously transformed with 
Flexi™ vector ligated with viral genes. Colony PCR was performed with primers 
described in Table 2.2 and used as confirmation of successful transformation and 
ligation. A: Lane 1- 100bp molecular marker, lane 2- positive control, lane 3- NL63 N 
gene colony (C)1, lane 4- NL63 C2, lane 5- NL63 N gene C3, lane 6- NL63 N gene C4, 
lane 7- negative control, lane 8 1Kbp molecular marker.  B: Lane1-  100bp molecular 
marker, lane 2- NL63 N gene C5, lane 3- NL63 N gene C6, lane 4- NL63 N gene C7, 
Lane 5- C8, Lane 6- C9, Lane 7- C10, lane 8- 1Kbp molecular marker. All successful 
amplifications of viral genes represent colonies, picked from agar plates, which were 
successfully transformed with the respective Flexi™-viral gene construct. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 : Colony PCR of KRX competent E. coli previously transformed with Flexi™ vector 
ligated with viral genes. Colony PCR was performed with primers described in Table (?) and 
used as confirmation of successful transformation and ligation. A: Lane 1- 100bp molecular 
marker, lane 2- positive control, lane 3- NL63 N gene colony (C)1, lane 4- NL63 C2, lane 5- NL63 N 
gene C3, lane 6- NL63 N gen  C4, lane 7- negative control, lane 8 1Kbp molecular marker.  B:
Lane1-  100bp molecular marker, lane 2- NL63 N gene C5, lane 3- NL63 N gene C6, lane 4- NL63 
N gene C7, Lane 5- C8, Lane 6- C9, Lane 7- C10, lane 8- 1Kbp molecular marker. All successful 
amplifications of viral genes represent colonies, picked from agar plates, which were successfully 
transformed with the respective Flexi™-viral gene construct. 
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3.3.1 Mammalian Expression Studies of HCoV-NL63 N, M and E proteins 
The DNA constructs that was given as a kind gift and used in this thesis were 
previously cloned into the pCAGGS vector and the positive control in a pXJ 40 vector 
for expression in a mammalian cell culture system (Table 2.3). 
3.3.2. Verification of recombinant plasmid 
3.3.2.1 Restriction Endonuclease Digest 
 Initial digestion of pCAGGS-N-HA, pCAGGS-M-HA and pCAGGS-E-HA plasmids 
DNA, to verify the presence of the correct genes, with EcoRI and Not1 excised 
1100bp, 700bp and 274bp DNA fragments respectively (Fig.3.13). This is in 
agreement with the size of HCoV-NL63 N, M and E gene nucleotide sizes found on 
the NCBI website with accession numbers YP_003771.1, YP_003770.1 and 
YP_003769.1 respectively. Two bands for each construct were observed, thus 
confirming that the vectors harbour the respective genes of interest (Fig.13. Lanes 1, 2 
and 3).  
This is an indication that correct restriction endonucleases were selected and optimal 
conditions were used for its proper functioning, thereby avoiding “star activity”. The 
latter is the ability of a restriction enzyme to under non-optimal conditions cleave 
DNA sequences that are similar, but not identical, to the recognition site of the 
enzyme. BamH1 and EcoR1 are notorious for its star activity. Table 3.3 summarises 
the characteristics of the restriction enzymes used in this application. 
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Table 3.3 : Restriction enzymes characteristics 
Restriction 
Enzyme 
Sequence Incubation 
Temperature  
Heat 
Inactivation 
PCR 
BamH1 G↓GATCC 37  N 100% 
EcoR1  G↓AATTC 37 Y 50% 
Not 1 GC↓GGCCGC 37 Y  
Xho1 C↓TCGAG 37 Y < 5% 
Y: Indicates that the enzyme can be inactivated by heat (15 minutes at +65°C 
unless otherwise stated) 
N: Indicates that the enzyme cannot be inactivated by heat and needs an 
alternative procedure (eg. EDTA treatment) 
PCR: Percentage of enzyme activity in a standard PCR Mix (= 10 mM Tris HCl, 
pH 8.3 at +20°C, 50 mM KCl, 1.5 mM MgCl2, λ-substrate DNA, 200 μM 
dNTP’s and 2.5 U Taq DNA Polymerase in a final volume of 100 μl) 
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Figure 3.13: Restriction Enzyme Digest of pCAGGS plasmid constructs 
with Eco-R1 and Not 1. Lane M: 100bp molecular marker. Lane 1 : HCoV-
NL63 N-gene (± 1100bp); Lane 2 : HCoV-NL63 E-gene (± 274bp); Lane 3 : 
HCoV-NL63 M-gene (± 700bp). 
 
3.3.3. Plasmid Purification (Midi-Prep) 
The purified plasmid DNA obtained from the NucleoBond® AX midi-prep 
(Macherey-Nagel) system is suitable for use in the most demanding molecular biology 
applications; including transfection, in vitro transcription, automated or manual 
sequencing, cloning, hybridization and PCR. For this reason, this assay kit was 
selected to optimise plasmid yield for more efficient transfection results. 
Large-scale plasmid extractions (midi-prep) were performed and the recombinant 
plasmids were characterized by restriction endonuclease digestion using a 1% agarose 
N 
M 
E 
 pCAGGS  (±4.7 
kb) 
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gel electrophoresis, as well as by nucleotide sequencing (Inqaba) of the cloned insert 
using reverse M13 universal primers (See Appendix for sequencing results) . The 
results obtained in Fig.3.14 corresponded exactly to the previous enzyme digest of 
pCAGGS-N-HA, pCAGGS-M-HA and pCAGGS-E-HA recombinant plasmids with 
EcoRI and Not1. 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Restriction Enzyme Digest of pCAGGS (± 4.7 kb) plasmid 
constructs with Eco-R1 and Not 1 for Verification. Lane M : 100bp molecular 
marker. Lane 1 : HCoV-NL63 N-gene (± 1100bp); Lane 2 : HCoV-NL63 M-gene 
(±700bp); Lane 3 : HCoV-NL63 E-gene (± 274bp) and Lane 4 : GST-HA 
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3.3.4 Quantification of plasmids  
 According to the manufacturer, the AX 100 (Midi) column should, on average, yield 
20–100 μg plasmid DNA. However, a much lower total plasmid yield of ± 1.5ug/ul 
was consistently achieved in this thesis. There could be various possible reasons for 
this low plasmid yield such as: (i) the pH or salt concentrations of buffers may have 
been too high; (ii) the sample/lysate was too viscous, thereby causing the filtration of 
the lysate and flow rate of the column to be insufficient; (iii) the column may have 
been overloaded with nucleic acids; (iv) the plasmids may not have propagated well in 
the culture, therefore only a low concentration was present in the cleared lysate; (v) 
the alkaline lysis was inefficient; this happens when culture volume or pellet weight is 
too high; (vi) the lysate was incorrectly prepared; (vii) after storage below 20°C, the 
SDS in Buffer S2 may precipitate, causing inefficient lysis; or (viii) the lysis 
treatment may have been too harsh (Birnboim and Doly 1979). However, the plasmid 
yield was sufficient for the transfection process.  
 
3.3.5. Expression of HCoV-NL63 N, M and E proteins in Cos 7 cells 
The COS7 cell line was selected as the research tool, as it is known to be an excellent 
choice for transfection experiments using recombinant plasmids. In order to use these 
cells as transfection hosts, the cells are imbued with a genetic construct preceded by 
the SV40 promoter. Several well established methods for delivery of nucleic acids 
into mammalian cells exists. However no single technique alone is suitable for the 
multitude of different cellular systems used for transfection experiments. 
Lipofectamine 200 (Invitrogen) was used as the transfection reagent. This process 
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involves a lipid with an overall net positive charge. The cationic portion of the lipid 
molecule associates with the negatively charged nucleic acids, resulting in compaction 
of the nucleic acid in a liposome/ nucleic acid complex (Kabanov and Kabanov,1995) 
(Labat-Moleur et al, 1996), presumably from electrostatic interactions between the 
negatively charged nucleic acids and the positively charged head group of the 
synthetic lipid. For cultured cells, an overall net positive charge of the liposome/ 
nucleic acid complex generally results in higher transfer efficiencies, presumably 
because this allows closer association of the complex with the negatively charged cell 
membranes. Entry of the liposome complex into the cell may occur by the processes 
of endocytosis or fusion with the plasma membrane via lipid moieties of the liposome 
(Gao and Huang, 1995). Opti-MEM® which is a reduced serum media was used with 
the Lipofectamine 200 (Invitrogen) to aid in the cationic lipid transfection process.  
In order to analyse the transient expression of the transfected genes, cells were 
harvested 24 hours post-transfection. Harvesting the cells before this time resulted in a 
low yield of expressed proteins; this could be due to the fact that reporter genes are 
usually expressed between 24-48 hours post-transfection. Harvesting after 24 hours 
also resulted in a much lower protein yield - this could be due to a reduction in the 
cell’s proliferation rate. COS7 cells grow relatively fast; therefore, after more than a 
24 hour incubation period, the cells started to detach. When the cells die, different 
proteases and lysozymes are released, thereby degrading the expressed proteins in 
solution.   
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Figure 3.15: Western Blot Analysis of Expressed Proteins in COS7 
cells.Recombinant plasmids pCAGGS-N-HA; pCAGGS-M-HA and pCAGGS-
E-HA (HCoV-NL63 N,M and E gene cloned into vector pCAGGS which 
appends an N-terminal Haemagglutinin tag to expressed proteins) was 
transfected with Lipofectamine 2000 (Invitrogen) into a Cos 7 cell line (African 
green monkey cells) and grown at 37°C in 5% CO2 for 16 h. Cells were then 
lysed and the target protein detected on a Western Blot using rabbit anti-HA 
polyclonal (1:250) as a primary antibody and goat anti-Rabbit polyclonal 
secondary antibody (1:1000). The proteins were separated by SDS-PAGE 
electrophoresis using a 15% polyacrylamide gel @ 15 mAmps per gel. Lane M 
– pre-stained protein marker (kDa), Lane 1- GST, Lane 2 - NL63 N protein, 
Lane 3 - NL63 M protein, Lane 4 - NL63 E protein. 
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pCAGGS-N-HA, pCAGGS-M-HA and pCAGGS-E-HA was selected for expression 
studies. A 24 hour protein expression time course was run to access the expression 
characteristics of the N, M and E proteins in the COS7 mammalian cells. Fig.3.15 
shows the expression of N-HA, M-HA and E-HA at 24 hours. The cells were 
harvested; lysed and total proteins were separated on a 15% SDS-PAGE and Western 
Blotted.  The supernatant samples were subjected to immunoblotting with anti-HA 
antibody (Sigma). A very high concentration of antibodies in the ratio of 1:250 had 
been used in order to detect the expressed proteins. It is speculated that this is due to 
very low quality antibodies coupled with a low protein yield, as Dr M.Muller whom I 
received the recombinants from had also observed a low protein expression yield. The 
N-HA, M-HA and E-HA protein was detected as 43 kDa, 27kDa and ±9kDa proteins 
respectively (Fig 3.15). The anti-HA antibody specially detected the N, M and E 
proteins.  In figure 3.15 Lane 3 the M protein contains more than one band; this is 
thought to be due to interaction or aggregations with other viral or cellular proteins. 
The proteins detected, corresponds to the predicted protein sizes obtained from NCBI 
(Table 3.2) (Altschul and Koonin 1998).    
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3.3.6. Comparisons of Bacterial and Mammalian Expression of the HCoV-NL63  
Nucleocapsid protein. 
 
 
 
 
 
 
 
 
Fig 3.16: Expression of HCoV-NL63 in: (A) a mammalian cell system. 
Recombinant plasmid pCAGGS-N-HA (HCoV-NL63 N gene cloned into vector 
pCAGGS which appends an N-terminal Haemagglutinin tag to expressed 
proteins) was transfected with lipofectamine 2000 (Invitrogen) into a Cos 7 cell 
line (African green monkey cells) and grown at 37°C in 5% CO2 for 16 h. Cells 
were then lysed and the target protein detected on a Western Blot using rabbit 
anti-HA polyclonal (1:250) as a primary antibody and goat anti-Rabbit 
polyclonal secondary antibody (1:1000). (B) a bacterial cell system. Cleavage of 
the GST-tag from HCoV-NL63 full length N using ProTEV protease 
(Promega). NL63 N was reversed transcribed from viral RNA and PCR 
amplified using nucleocapsid specific primers. The N-gene was cloned into the 
pFLEXI
TM
 protein expression vector (Promega), which appends an N-terminal 
GST affinity tag. Protein expression was induced by addition of 0.1% 
Rhamnose (Promega). Lane 2: HCoV-NL63 GST N; Lane 5: HCoV-NL63 N 
with GST cleaved. (section B was done by my colleague Michael Berry as this 
formed part of our collaborative research paper on the characterization of 
HCoV-NL63 N-gene). 
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HCoV-NL63 genome is about ± 27 553 nucleotides in size, and has a typical 
coronavirus genome organization. It produces six separate mRNAs, with all potential 
ORFs encoding for viral proteins (Abdul-Rasool and Fielding 2010). N is expressed 
from distinct subgenomic (sg) mRNA 6, the most abundant sg mRNA (Pyrc, Jebbink 
et al. 2004). In order to determine the size of HCoV-NL63 N, recombinant GST-N 
plasmid was expressed in a bacterial system. It was then purified by affinity column 
and treated with TEV to remove the GST-tag, according to the manufacturer’s 
specification (Promega). The recombinant HCoV-NL63 N-HA was transfected and 
expressed in Cos-7 cells (Khan, Fielding et al. 2006). SDS-PAGE analysis of purified 
bacterial expressed protein (Figure 3.16A) and Western Blot analysis of total 
mammalian cell lysate (Figure 3.16B) showed ~50 kDa proteins which is larger than 
the size of the 42.6 kDa protein that had been predicted by our initial analysis 
(http://www.sciencegateway.org/tools/ proteinmw.htm). This difference in size 
showed that the protein was probably pre-, co- or post-translationally modified; the 
type of modification is yet to be investigated. Once determined the functions of this 
potential modifications could shed light on the possible roles of these proteins in 
HCoV-NL63 pathogenesis.  
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The World Health Organization estimates that about 20% of deaths in children younger than 
5 years old are due to acute lower respiratory tract infections. Several viruses have shown to 
be implicated in these infections, including rhinovirus, influenza viruses, parainfluenza 
viruses, respiratory syncytial viruses, adenoviruses and coronaviruses. Previous reports had 
indicated that human coronaviruses account for a significant number of hospitalizations for 
children under 18 years of age, accounting for 4.4% of all admissions for acute respiratory 
infections (Chiu, Chan et al. 2005). 
Human coronaviruses were first isolated in the 1960s and since then, HCoVs have been 
found to be mainly associated with respiratory tract illness, but can also cause enteric and 
central nervous system diseases. Until recently, only two human coronaviruses were known 
to science, i.e. HCoV-229E and HCoV-OC43. With the outbreak of SARS in 2003, a third 
previously unknown coronavirus was identified as the aetiological agent. SARS human 
coronavirus eventually spread from China to more than 30 countries and resulted in more 
than 800 fatalities worldwide, this equated to about a 10% mortality rate. Then in 2004, a 
fourth human coronavirus was isolated from a 7 month old child with respiratory symptoms. 
This virus was identified as a close relative of SARS-CoV and was named human 
coronavirus-NL63 (van der Hoek, Pyrc et al. 2004). The human coronavirus NL63 (HCoV-
NL63) is a clinically important virus; it mainly affects children, the elderly and 
immunocompromised.  
HCoV-NL63 infection usually results in mild respiratory tract disease but it has shown to be 
involved with more severe lower respiratory tract infections such as bronchiolitis, 
pneumonia, and croup. At a molecular level, this virus is assembled through interactions of 
its structural proteins, namely the spike (S), membrane (M), envelope (E) and nucleocapsid 
(N) proteins.  
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3 out of the 4 major structural proteins are characterized and analysed by means of 
bioinformatics tools and protein expression strategies. Special attention has been paid to 
conserved regions of coronavirus N-, M- and E- homologous, identification of 
transmembrane domains, hydrophobic and hydrophilic regions, putative phosphorylation, N-
linked glycosylation and myrostoilation sites, which could give insight into the functioning of 
the proteins. With the use of molecular research tools the N, M and E genes had been 
transfected into a mammalian cell system in order for it to be transiently expressed. 
Furthermore comparisons were made of the N protein expression in a bacterial and 
mammalian cell system.  
Bioinformatics tools had revealed 4 transmembrane regions found within the M-protein of 
HCoV-NL63 that differs slightly with research done on other coronaviruses in which only 3 
transmembrane domains are identified (Ruch and Machamer 2012) . This could be due to the 
use of different algorithms; however these results are confirmed with the use of hydropathy 
predictions. A single transmembrane domain had been observed in the E protein sequence, 
this shed s light on its topology as different topologies for the E protein had been proposed 
(Torres, Wang et al. 2005; Ye and Hogue 2007; Ruch and Machamer 2012).  This is an 
indication that the function of the E protein is not conserved amongst coronaviruses. Many 
questions have been derived from this. The E protein of HCoV-NL63 shares a high 
percentage sequence homology with HCoV-229E E protein. Could this be an indication that 
they share the same topology? And if so does the E protein of coronaviruses from the same 
group share the same topology? Seeing that the E protein function is not a conserved property 
amongst coronaviruses, does this protein still remain to be a major structural protein in 
coronavirus assembly and pathogenesis?  All of these questions remain to be answered and 
can serve as a prelude to further studies.  
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For the N protein sequence a highly conserved region was found using multiple sequence 
alignment tools and a SR (serine) rich motif had been identified. The N protein also showed 
to be highly phosphorylated at multiple serines, and is also highly immunogenic (Berry 
2012). This conserved region of ± 8 amino acids may be responsible for the mediating of 
RNA binding. This region is also found within the disordered region of the N protein 
sequence. This is evident that these sites of phosphorylation and increased immmunogenecity 
can be directed to its SR-rich region that falls within the disordered state. Could this be a 
great potential target for antiviral strategies? As disordered regions of a protein have no fixed 
tertiary structure, thereby allowing access to binding sites.  
Even though all of these various characteristic have been identified with the use of 
bioinformatics tools, it is still necessary to prove these results in-vitro. In order to do a 
comparison of the N protein expression in a bacterial and mammalian system, a recombinant 
GST-N had been expressed in a bacterial system, purified by an affinity column and treated 
with TEV to remove the GST-tag. Also, the recombinant HCoV-NL63 N-HA was transfected 
and expressed in COS7 cells. On analysis of the two protein expression systems a 50kDa 
protein had been shown, which is larger than the size of 42.6 kDa protein that had been 
predicted (Berry 2012). This discrepancy in size showed that the protein was probably pre-, 
co- or post-translationally modified, this type of modification is still to be investigated in 
future studies.  
To further characterise the N-, M-, and E-proteins of HCoV-NL63 in an in vitro model, it had 
been expressed in COS7 cells. Extensive optimization had been done in order forthese 
proteins to be expressed. These include only GST-HA ( positive control) had been detected 
on the blot, which could have been due to a very low concentration of DNA used in 
transfection, the transfection agent (lipofectamine) was either degraded or lethal to the cells; 
the cells were not accepting the DNA readily, thereby not expressing the proteins. The 
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detection method could have been faulted, such as either the primary or secondary antibody 
had degraded. The problem seemed to have been 1 of 3 things or a collaboration of all 3, as 
the proteins were detected after being treated with a high concentration of primary antibody 
(1:250), which means the antibody could have been of low quality or a very low level of 
proteins were expressed by the COS7 cells, orthe lyses buffer was not releasing the proteins 
well enough from the cell membrane portion. These heterologous expressed proteins can now 
serve as the basis of several post expression studies. 
This dissertation had provided new knowledge of how HCoV-NL63 assembles inside an 
infected cell. Such knowledge will help us to identify major targets for antiviral drug 
development, not only for HCoV-NL63 but for other coronaviruses too, as a new coronavirus 
had been identified in September 2012 and had already resulted in two fatalities.    
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Appendix 1 
 
 
Appendix 1: Sequence verification of the cloned SARS N-gene. 
Cloned genes were sequenced with the T7 terminator primer. T7 primer sites lie downstream of the 
cloning site and upstream of the GST fusion tag sequence. As the polymerase can only read ±800bp 
into the sequence, the forward primer is not suitable as only the GST gene would be sequenced 
(Data is relevant for appendix 1-5). SARS_FL  represents the sequence for the SARS N-gene obtained 
from ncbi with accession number AY360146.1, where SARS represents the sequence of the cloned 
SARS N-gene. 
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Appendix 2 
 
 
 
Appendix 2: Sequence verification of the NL63 full length N-gene 
NL63_FL represents the sequence for the NL63 N-gene obtained from NCBI with accession number 
DQ846901.1, where N1 represents the sequence of the cloned NL63 N-gene. 
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Appendix 4 
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Appendix 5 
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Appendix 6 
 
 
 
 
Appendix 9: Kyte-Doolittle Hydropathy scores. These scores are based on the values given by the 
original Kyte-Doolittle paper  (Kyte and Doolittle 1982). 
 
  
 
 
 
 
 
 
